Survey
* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project
Download 18th Annual Scientific Assembly - Heart Failure Society of America
Document related concepts
Coronary artery disease wikipedia , lookup
Rheumatic fever wikipedia , lookup
Electrocardiography wikipedia , lookup
Remote ischemic conditioning wikipedia , lookup
Antihypertensive drug wikipedia , lookup
Management of acute coronary syndrome wikipedia , lookup
Arrhythmogenic right ventricular dysplasia wikipedia , lookup
Cardiac contractility modulation wikipedia , lookup
Heart failure wikipedia , lookup
Heart arrhythmia wikipedia , lookup
Dextro-Transposition of the great arteries wikipedia , lookup
Transcript
2014 PROGRAM 18th Annual Scientific Assembly $BFTBST1BMBDFt-BT7FHBT/7 4FQUFNCFSo IN PATIENTS WITH HEART FAILURE, AN INCREASED HEART RATE OF ≥70 BPM CAN INCREASE HIS RISK For the over 5 million American adults living with heart failure, an increased heart rate of ≥ 70 bpm (among other factors including diabetes and reduced LVEF) can increase the risk of hospitalization and mortality.1,2 • 25% of heart failure patients are readmitted to the hospital within 30 days and 50% are readmitted within 6 months.3-5 • Even with treatment, heart failure patients may still have increased heart rates, which may put them at greater risk for CV events.6,7,8 BOOTH 607 Visit HeartRateMatters.com to learn about the role heart rate can play in heart failure References 1. Go AS, Mozaffarian D, Roger VL, et al. Circulation. 2014;129:e28-e292. 2. Castagno D, Skali H, Takeuchi M, et al. J Am Coll Cardiol. 2012;59:1785-1795. 3. Jencks SF, Williams MV, Coleman EA. N Engl J Med. 2009;360:1418-1428. 4. Krumholz HM, Merrill AR, Schone EM, et al. Circ Cardiovasc Qual Outcomes. 2009;2:407-413. 5. Krumholz HM, Chen, Y-T, Wang Y, et al. Am Heart J. 2000;139:72-77. 6. Cucherat M. Eur Heart J. 2007;28:3012-3019. 7. Fonarow GC, et al. Circulation. 2010;122:585-596. 8. Fonarow GC, et al. Arch Intern Med. 2007;167:1493-1502. bpm = beats per minute; CV = cardiovascular; LVEF = left ventricular ejection fraction. © 2014 Amgen Inc. All Rights Reserved. USA-998-100250 20 14 H FS A AN NU AL SCI ENT I FI C M E ET I NG Table of Contents President’s Message .................................................................................4 About the HFSA .....................................................................................6 Sunday, September 14 Monday, September 15 B:11.25 in S:10 in T:10.875 in Tuesday, September 16 Wednesday, September 17 Posters Exhibit Hall SE PT E MB ER 1 4- 17 L AS V E GAS , NE VA D A 3 20 14 H FS A AN NU AL SCI ENT I FI C M E ET I NG President’s Message Core Organizational Values in Strategic Plan: Advocacy Membership Communications Other Successful Initiatives SE PT E MB ER 1 4- 17 L AS V E GAS , NE VA D A 4 20 14 H FS A AN NU AL SCI ENT I FI C M E ET I NG Meeting Related Successes Thomas Force, MD President, Heart Failure Society of America, 2012-14 SE PT E MB ER 1 4- 17 L AS V E GAS , NE VA D A 20 14 H FS A AN NU AL SCI ENT I FI C M E ET I NG About the HFSA The HFSA is dedicated to: Society Membership Information SE PT E MB ER 1 4- 17 L AS V E GAS , NE VA D A 6 20 14 H FS A AN NU AL SCI ENT I FI C M E ET I NG Executive Council 2014 Scientific Program Committee Co-Chairs: Members Members Thank You October. A call for proposals for 2015 will go out in SE PT E MB ER 1 4- 17 L AS V E GAS , NE VA D A 20 14 H FS A AN NU AL SCI ENT I FI C M E ET I NG General Meeting Information Meeting Location CME Accreditation/Registration Registration Hours Included in Registration Fee Meeting Sessions Online Opening Reception Poster Receptions SE PT E MB ER 1 4- 17 L AS V E GAS , NE VA D A 20 14 H FS A AN NU AL SCI ENT I FI C M E ET I NG General Meeting Information Food Policy No Smoking Policy Special Needs Annual Business Meeting Questions Speaker Ready Room Press Room SE PT E MB ER 1 4- 17 L AS V E GAS , NE VA D A 20 14 H FS A AN NU AL SCI ENT I FI C M E ET I NG General Meeting Information Exhibit Hall Schedule Email from the Exhibit Hall WiFi Special Activities in the Exhibit Hall Clinical Trial Row Clinical Updates Hands-on Workshops SE PT E MB ER 1 4- 17 L AS V E GAS , NE VA D A 20 14 H FS A AN NU AL SCI ENT I FI C M E ET I NG General Meeting Information Poster Sessions Posters on display: Presenters at their posters: 2014 HFSA Satellite/Scientific Program Supporting Companies Satellite Symposium Support: Meeting Support: Hands-on Workshop Support (CME): Workshop Support (non-CME): Advertising Support: Corporate Membership: Clinical Update Support (non-CME): SE PT E MB ER 1 4- 17 L AS V E GAS , NE VA D A 20 14 H FS A AN NU AL SCI ENT I FI C M E ET I NG Continuing Education Credit Information Physicians: AMA PRA Category 1 Credits.™ Nurses: Pharmacists: Satellite Symposia Physicians: AMA PRA Category 1 Credit.™ Nurses: Presenter/Planner Disclosure Information SE PT E MB ER 1 4- 17 L AS V E GAS , NE VA D A 20 14 H FS A AN NU AL SCI ENT I FI C M E ET I NG Continuing Education Credit Information Following this meeting, attendees will be able to: Competencies Addressed • Patient care SE PT E MB ER 1 4- 17 L AS V E GAS , NE VA D A 20 14 H FS A AN NU AL SCI ENT I FI C M E ET I NG Continuing Education Credit Information Evaluations symposia. Pharmacists Meeting Content Liability Statement SE PT E MB ER 1 4- 17 L AS V E GAS , NE VA D A 20 14 H FS A AN NU AL SCI ENT I FI C M E ET I NG 2014 Abstract Reviewers Nancy M. Albert, RN, PhD Michael M. Givertz, MD David E. Lanfear, MD, MS Juanita Reigle MSN, ACNP Inder S. Anand, MD, PhD Lee R. Goldberg, MD, MPH Ann S. Laramee, APRN, MS Joseph G. Rogers, MD J. Malcolm O. Arnold, MD Steven Goldman, MD Terry A. Lennie, RN, PhD Heather J. Ross, MD Linda S. Baas, RN, PhD, ACNP Stephen S. Gottlieb, MD Daniel J. Levine, MD Stuart D. Russell, MD Vera Barton-Caro, PhD, RN, FNP-BC, CHFN Barry H. Greenberg, MD Douglas L. Mann, MD Douglas B. Sawyer, MD, PhD Asa B. Gustafsson, PhD Kenneth B. Margulies, MD Marc J. Semigran, MD Paul J. Mather, MD Jagmeet P. Singh, MD, PhD Karol Harshaw-Ellis, MSN Shawn M. Merhaut, MSN, NP William G. Stevenson, MD Paul A. Heidenreich, MD, MS Alan B. Miller, MD Lynne Warner Stevenson, MD J. Thomas Heywood, MD Leslie W. Miller, MD Garrick C. Stewart, MD Tamara B. Horwich, MD, MS Debra Moser, RN, PhD WH Wilson Tang, MD Steven R. Houser, PhD Robert L. Page, II, PharmD, MSPH John R. Teerlink, MD Sharon A. Hunt, MD Peter S. Pang, MD Jeffrey J. Teuteberg, MD Brian E. Jaski, MD Richard D. Patten, MD James E. Udelson, MD Stuart D. Katz, MD J. Herbert Patterson, PharmD Hector O. Ventura Michael S. Kiernan, MD Michael G. Petty, RN, PhD Linda L. Wick, RN, MSN, CNP Robb D. Kociol, MD Ileana L. Piña, MD Burns Blaxall, PhD Biykem Bozkurt, MD, FACC John C. Burnett Jr, MD Javed Butler, MD, MPH Sheryl L. Chow, PharmD Sean P. Collins, MD, MSc Akshay S. Desai, MD, MPH Anita Deswal, MD, MPH Gerald W. Dorn II, MD Mark H. Drazner, MD Lorraine S. Evangelista, RN, PhD Gregory A. Ewald, MD Anecita P. Fadol, NP G. Michael Felker, MD Suzanne Wingate, RN, PhD Marvin A. Konstam, MD Sean P. Pinney, MD Michael R. Zile, MD Maria I. Kontaridis, PhD SE PT E MB ER 1 4- 17 L AS V E GAS , NE VA D A 20 14 H FS A AN NU AL SCI ENT I FI C M E ET I NG Faculty 2014 HFSA Annual Scientific Meeting and Satellite Symposia John Cleland, MD Keith D. Aaronson, MD, MS Linda Baas, PhD, RN William T. Abraham, MD Carol C. Ballew, RN, MSN, ACNP, Meredith A. Brisco, MD, MSCE Robert J. Cody, MD, MBA CHFN - Michael A. Acker, MD Robert Baumgartner, MD Matthew Budoff, MD Jay N. Cohn, MD Philip B. Adamson, MD Jonathan Beaudoin, MD Luke J. Burchill, MD Sean P. Collins, MD, MSC Sirtaz Adatya, MD Tarek Bekfani, MD John C. Burnett Jr., MD Paolo C. Columbo, MD Sadeer Al-Kindi, MD Joseph R. Betancourt, MD, MPH Javed Butler, MD, MPH Monica M. Colvin, MD Nancy M. Albert, RN, PhD Ronald D. Berger, MD, PhD Allen Cadavero, MSN, RN Pamela S. Combs, PhD, RN, MCS Robert M. Califf, MD Nakela L. Cook, MD, MPH Larry A. Allen, MD, MHS Biykem Bozkurt, MD Martin A. Alpert, MD Julie T. Bidwell, RN, BSN Jan Cameron, PhD, MHSc Leslie T. Cooper, MD Amrut V. Ambardekar, MD Robert Blanton, MD Justin Canada, RCEP Maria Rosa Costanzo, MD Inder S. Anand, MD, PhD Burns C. Blaxall, PhD Thomas P. Cappola, MD, ScM Ramesh Daggubati, MD Mads J. Andersen, MD, PhD John P. Boehmer, MD Horng H. Chen, MD Patricia Davidson, PhD, MEd, RN Silvio Antoniak, PhD Roberto Bolli, MD Sheryl L. Chow, PharmD Teresa De Marco, MD Abbas Ardehali, MD Barry A. Borlaug, MD Eugene Chung, MD Prakash Deedwania, MD SE PT E MB ER 1 4- 17 L AS V E GAS , NE VA D A 20 14 H FS A AN NU AL SCI ENT I FI C M E ET I NG Faculty 2014 HFSA Annual Scientific Meeting and Satellite Symposia Gregory A. Ewald, MD Marie Galvao, RN, MSN, ANP-BC Kathleen Halvey, NP-BC Anecita Fadol, PhD, FNP Mihai Gheorghiade, MD Muhammad Hammadah, MD Erin K. Donaho, ANP Beth Fahlberg, PhD Nisha A. Gilotra, MD Joshua M. Hare, MD Stavros G. Drakos, MD, PhD James C. Fang, MD Michael M. Givertz, MD Karol Harshaw-Ellis, DNP Mark H. Drazner, MD Anthony Fargnoli, MS E. Kevin Heist, MD, PhD Paul J. Hauptman, MD Mark Dunlap, MD Savitra E. Fedson, MD Lee R. Goldberg, MD, MPH Anna R. Hemnes, MD Shannon M. Dunlay, MD, MS Gregory J. Fermann, MD Steven Goldsmith, MD Joshua L. Hermsen, MD Jean-Bernard Durand, MD Gerasimos Filippatos, MD Sarah J. Goodlin, MD Adrian F. Hernandez, MD Zubin J. Eapen, MD Mona Fiuzat, PharmD Stephen S. Gottlieb, MD Ray E. Hershberger, MD Howard J. Eisen, MD Richard Fogel, MD Kathleen Grady, PhD, ANP J. Thomas Heywood, MD Mohamed A. El-Shahawy, MD, MPH, MHA - Gregg C. Fonarow, MD Lucinda Graven, PhD Joseph A. Hill, MD, PhD Tonya Elliott, MSN, RN Thomas L. Force, MD Barry H. Greenberg, MD Godtfred Holmvang, MD Justin L. Grodin, MD Shunichi Homma, PharmD Richard Ha, MD Steven R. Houser, PhD Deborah B. Diercks, MD Meghan E. Emig, MPAS, PA-C Jerry D. Estep, MD Ellin F. Gafford, MD SE PT E MB ER 1 4- 17 L AS V E GAS , NE VA D A 20 14 H FS A AN NU AL SCI ENT I FI C M E ET I NG Faculty 2014 HFSA Annual Scientific Meeting and Satellite Symposia Nancy Houston-Miller, RN, PhD Michael S. Kim, MD Ann S. Laramee, MS, APRN Donna M. Mancini, MD Sandeep M. Jani, MD, MPH Lisa Kitko, PhD, RN Shane J. LaRue, MD Douglas L. Mann, MD James L. Januzzi, MD Dalane W. Kitzman, MD Olga Laur, MS Eduardo Marban, MD, PhD Ali Javaheri, MD, PhD Liviu Klein, MD, MS Hilary Law, MN, RN Kenneth B. Margulies, MD John Lynn Jefferies, MD, MPH Jon A. Kobashigawa, MD Daniel J. Lenihan, MD Bradley Maron, MD Lee W. Jordan, MD Walter J. Koch, PhD Annarosa Leri, MD Linda H. Martin, RN Susan Joseph, MD Robb D. Kociol, MD Phillip D. Levy, MD, MPH Paul J. Mather, MD Corrine Y. Jurgens, PhD, RN Issei Komuro, MD, PhD Wayne C. Levy, MD Mathew S. Maurer, MD Eldrin F. Lewis, MD, MPH Edwin C. McGee Jr., MD Marvin A. Konstam, MD Gregory D. Lewis, MD Dennis M. McNamara, MD Navin K. Kapur, MD Robert Kormos, MD Robert C. Like, MD Nita Meaux, RN, CRNI Jason N. Katz, MD, MHS Arun Krishnamoorthy, MD JoAnn Lindenfeld, MD Mandeep R. Mehra, MD Steven Lipshultz, MD Gina G. Mentzer, MD Alan S. Maisel, MD Deborah Meyers, MD Andreas P. Kalogeropoulos, MD, Alan T. Kono, MD MPH, PhD - Stuart D. Katz, MD Michael S. Kiernan, MD Sudhir S. Kushwaha, MD SE PT E MB ER 1 4- 17 L AS V E GAS , NE VA D A 20 14 H FS A AN NU AL SCI ENT I FI C M E ET I NG Faculty 2014 HFSA Annual Scientific Meeting and Satellite Symposia Edward J. Miller, MD, PhD Linda K. Ottoboni, RN, MS Ileana L. Pina, MD Stuart D. Russell, MD Leslie W. Miller, MD Milton Packer, MD Sean P. Pinney, MD John J. Ryan, MD Debra Moser, DNSc, RN Francis D. Pagani, MD, PhD Bertram Pitt, MD Hani Sabbah, PhD Wilfried Mullens, MD, PhD Robert Lee Page II, PharmD Ioana Preston, MD Mitchell T. Saltzberg, MD Srihari S. Naidu, MD Salpy V. Pamboukian, MD Giuseppe Puccia, MD Douglas B. Sawyer, MD, PhD Peter S. Pang, MD Kismet Rasmusson, DNP, FNPBC - Leslie A. Saxon, MD Douglas D. Schocken, MD Jean M. Nappi, PharmD Soon J. Park, MD Jose N. Nativi Nicolau, MD Kimberly A. Parks, DO Gordon R. Reeves, MD Joan Forte Scott, MBA, RN, NE-BC Karl Nelson, RN, MBA Chetan B. Patel, MD Carolyn Reilly, PhD, RN Marc J. Semigran, MD Jennifer L. Nixon, DNP Kristen K. Patton, MD Jonathan D. Rich, MD Atmaan P. Shah, MD Christopher M. O'Connor, MD Sara C. Paul, DNP, FNP Jo Ellen Rodgers, PharmD Monica Shah, MD Sasha Opotowsky, MD Michael G. Petty, PhD, RN Joseph G. Rogers, MD Beno Oppenheimer, MD Jennifer L. Peura, MD Carolyn M. Rosner, MSN Alok Sharma, MD Linda J. Ordway, RN, MS, ANCP-BC - Duc Thinh Pham, MD Frank Ruschitzka, MD Hiroaki Shimokawa, MD, PhD Mayo Foundation SE PT E MB ER 1 4- 17 L AS V E GAS , NE VA D A 20 14 H FS A AN NU AL SCI ENT I FI C M E ET I NG Faculty 2014 HFSA Annual Scientific Meeting and Satellite Symposia Julie A. Shinn, PhD, RN Gary Sweeney, PhD Eric Velazquez, MD Edward TH Yeh, MD Domenic A. Sica, MD Nancy K. Sweitzer, MD, PhD Joseph Verbalis, MD Payman Zamani, MD Bruce Siegel, MD, MPH Eiki Takimoto, MD, PhD Frederik Verbrugge, MD Mark Jay Zucker, MD Jagmeet Singh, MD, PhD W.H. Wilson Tang, MD Mary N. Walsh, MD David L. Smull, DO John R. Teerlink, MD Yibin Wang, PhD Scott D. Solomon, MD Jeffrey M. Testani, MD Frederick G. Welt, MD Jeffrey J. Teuteberg, MD Christopher Sparrow, MD Isabel Torres Courchoud, MD Linda L. Wick, RN, MSN, CNP Randall C. Starling, MD, MPH Robin C. Trupp, PhD, RN Miles D. Witham, MD, PhD Lynne Warner Stevenson, MD Ming Fen Tsai, PhD Ronald M. Witteles, MD William G. Stevenson, MD James E. Udelson, MD Y. Joseph Woo, MD Garrick C. Stewart, MD Nir Uriel, MD Sara E. Wordingham, MD Karen K. Stout, MD Jop van Berlo, MD, PhD Joseph Wu, MD, PhD Mark A. Sussman, MD Paul D. Varosy, MD Clyde W. Yancy, MD, MSc SE PT E MB ER 1 4- 17 L AS V E GAS , NE VA D A 20 14 H FS A AN NU AL SCI ENT I FI C M E ET I NG Program-at-a-Glance Sunday September 14 10:00 AM-12:00 PM Clinical Fundamentals I: Hemodynamics in Heart Failure: What You Need to Know Milano I 10:00 AM-12:00 PM Contemporary Issues in Pulmonary Hypertension Milano III 10:00 AM-12:00 PM Heart Failure Palliative Care: Critical Issues Milano VII 12:00 PM-2:30 PM Hands-on Workshop CRT: Indications, Optimization, Device Interrogation, Interpreting the Data, Troubleshooting 3:00 PM-5:30 PM Can We Prevent Heart Failure? 3:00 PM-5:30 PM Challenges in Caring for the Elderly Patient with a VAD Milano V 3:00 PM-5:30 PM Excellence in Basic Science:Translational Targets Move to the Clinic Milano VII 3:00 PM-5:30 PM Hemodynamic Impact of Drugs and Devices 3:00 PM-5:30 PM Hands-on Workshop ( CRT: Indications, Optimization, Device Interrogation, Interpreting the Data, Troubleshooting SE PT E MB ER 1 4- 17 L AS V E GAS , NE VA D A 20 14 H FS A AN NU AL SCI ENT I FI C M E ET I NG Program-at-a-Glance Monday September 15 6:30 AM-7:30 AM Light Breakfast Milano Foyer 7:00 AM-8:00 AM Satellite Symposium: Hyponatremia in Heart Failure: Incorporating Practice Recommendations into Clinical Practice Milano III 7:00 AM-8:00 AM Satellite Symposium: Imaging Sympathetic Innervation in Heart Failure: Window into Pathology and Outcome Milano VIII 7:00 AM-8:00 AM Satellite Symposium: Remote Monitoring of Patients with Heart Failure: New Developments Milano V 8:05 AM-10:00 AM Lifetime Achievement Award Plenary Session: The Challenge of Care Disparities in Heart Failure Augustus I 10:30 AM-12:00 PM Controversies and Challenges in Device Therapy 10:30 AM-12:00 PM Predicition Is Hard, Especially About the Future: Dealing with Uncertainty in Risk Assessment Milano VIII 10:30 AM-12:00 PM Heart Failure Trials: The Year in Review Augustus I 10:30 AM-12:00 PM Venous Congestion in Heart Failure: The Dark Side of the Moon Milano VII 10:30 AM-1:00 PM Hands-on Workshop Acute Management of Cardiogenic Shock with Peripherally Implanted Devices 12:15 PM-1:15 PM How to Develop a Comprehensive Heart Failure Clinic in a Community Setting Milano VII 12:15 PM-1:15 PM How to Use Biomarkers in Clinical Practice Milano V 12:15 PM-1:15 PM How to Assess Frailty and Make Appropriate Activity Recommendations Milano VIII 12:15 PM-1:15 PM How to Diagnose and Treat LVAD Complications Milano I 12:15 PM-1:15 PM Rapid Fire Abstracts I Milano III SE PT E MB ER 1 4- 17 L AS V E GAS , NE VA D A 20 14 H FS A AN NU AL SCI ENT I FI C M E ET I NG Program-at-a-Glance Monday September 15 (continued) 1:30 PM-3:00 PM Guideline Session: Milano I 1:30 PM-3:00 PM Heart Failure in Adults with Congenital Heart Disease Milano VIII 1:30 PM-3:00 PM Heart Failure in Cancer Patients and Survivors: Prevention, Monitoring and Management Milano V 1:30 PM-3:00 PM Update on Stem Cell Clinical Trials Milano VII 1:30 PM-4:00 PM Hands-on Workshop Acute Management of Cardiogenic Shock with Peripherally Implanted Devices 3:30 PM-5:00 PM Why the First Six Hours Are Not Like the Next 18 Hours 3:30 PM-5:00 PM Central Congestion in Obesity: Is the Heart an Innocent Bystander? Milano VIII 3:30 PM-5:00 PM Late Breaking Clinical Trials Augustus I 3:30 PM-5:00 PM Trends and Treatment Options for LVAD Thrombosis Milano V SE PT E MB ER 1 4- 17 L AS V E GAS , NE VA D A 20 14 H FS A AN NU AL SCI ENT I FI C M E ET I NG Program-at-a-Glance Tuesday September 16 6:30 AM-8:00 AM Light Breakfast Milano Foyer 7:00 AM-8:00 AM Clinical Fundamentals II: Beyond Peak Oxygen Consumption: New Insights into CPET Milano I 7:00 AM-8:00 AM Satellite Symposium: Managing Hyperkalemia in Heart Failure: A Shifting Paradigm? Milano III 7:00 AM-8:00 AM Satellite Symposium: Heart Failure Patients with Mitral Regurgitation: New Guidelines, New Options Milano V 8:10 AM-10:00 AM Clinical Excellence in Nursing Nursing Leadership Awards Plenary Session: Comparative Effectiveness Research: The Time Has Come Augustus I 10:00 AM-12:00 PM Hands-on Workshop Patient Selection, Management and Troubleshooting Durable VADs 10:30 AM-12:00 PM Case Discussion Milano I 10:30 AM-12:00 PM Heart Failure Clinical Trials: Future Challenges and Directions Milano V 10:30 AM-12:00 PM JNC Young Investigator Award: Basic Science Milano VIII 10:30 AM-12:00 PM JNC Young Investigator Award: Clinical/Integrative Milano VII 10:30 AM-12:00 PM Nursing Research Award Milano III 12:15 PM-1:15 PM How to Run an Effective Clinical Research Program Milano VII 12:15 PM-1:15 PM Hoping for the Best, Planning for the Worst Milano VIII 12:15 PM-1:15 PM How to Develop a Shared Care Program for LVAD Patients Milano I 12:15 PM-1:15 PM How to Transition Patients into the Community Milano V 12:15 PM-1:15 PM Rapid Fire Abstracts II Milano III SE PT E MB ER 1 4- 17 L AS V E GAS , NE VA D A 20 14 H FS A AN NU AL SCI ENT I FI C M E ET I NG Program-at-a-Glance Tuesday September 16 (continued) 12:30 PM-2:30 PM Hands-on Workshop Patient Selection, Management and Troubleshooting Durable VADs 1:30 PM-3:00 PM Challenges and Controversies in Heart Failure Pharmacology Milano III 1:30 PM-3:00 PM Hyde Park Session Augustus I 1:30 PM-3:00 PM International Session Milano VII 1:30 PM-3:00 PM Reverse Remodeling and Myocardial Recovery Milano VIII 3:00 PM-5:00 PM Hands-on Workshop Patient Selection, Management and Troubleshooting Durable VADs 3:30 PM-5:00 PM cGMP Activating Pathways in Heart Failure: Clinical and Basic Insights Milano VIII 3:30 PM-5:00 PM Debates Milano I 3:30 PM-5:00 PM Heart Failure and Cardiac Rehabilitation: What Clinicians Need to Know Milano VII 3:30 PM-5:00 PM How to Select Patients for Advanced Therapies (ISHLT Joint Session) Milano V SE PT E MB ER 1 4- 17 L AS V E GAS , NE VA D A 20 14 H FS A AN NU AL SCI ENT I FI C M E ET I NG Program-at-a-Glance Wednesday September 17 7:00 AM-8:00 AM Clinical Fundamentals III: The Basics of Mechanical Circulatory Support Milano V 8:30 AM-10:00 AM HFpEF: What We Do and Don't Know Milano V 8:30 AM-10:00 AM Improving Patient Satisfaction Scores: Strategies to Make Them Love You Milano VII 8:30 AM-10:00 AM Emerging Roles for Advanced Imaging in Unexplained Cardiomyopathy Milano VIII 8:30 AM-10:00 AM New Challenges in Cardiac Transplantation Milano III 10:30 AM-12:00 PM Not All Readmissions Should Be Avoided: When to Readmit Patients with Heart Failure Milano III 10:30 AM-12:00 PM Right Ventricular Failure After LVAD Implantation Milano V 10:30 AM-12:00 PM 50 Shades of Technology in the Management of Heart Failure Milano VII 12:00 PM SE PT E MB ER 1 4- 17 L AS V E GAS , NE VA D A 20 14 H FS A AN NU AL SCI ENT I FI C M E ET I NG Program-at-a-Glance HFSA 2014 Annual Scientific Meeting Special Events and Exhibit Hall Activities Sunday September 14 1:30 PM-3:00 PM Speed Mentoring and Meet and Greet Florentine 5:00 PM-6:30 PM Nursing Reception 5:00 PM-6:30 PM Pharmacy Reception 6:00 PM-8:00 PM Opening Reception Exhibit Hall 6:30 PM-7:30 PM Presenters at their posters Exhibit Hall 6:30 PM-7:15 PM Clinical Update The Role of Neurohormonal Balance in Cardiac Remodeling and Progression of Heart Failure Exhibit Hall 8:30 PM-10:00 PM Early Career Reception Rainman Suite Monday September 15 10:00 AM-4:00 PM Hands-on Workshop on Sleep Apnea 12:30 PM-1:15 PM Clinical Update Considering Heart Rate in Cardiovascular Disease: A Focus on Heart Failure Exhibit Hall 5:00 PM-6:30 PM Poster Reception Exhibit Hall 5:30 PM-6:30 PM Presenters at their posters Exhibit Hall 5:45 PM-6:30 PM Clinical Update The Evidence Behind the Evidence: A Deeper Dive Into the Management of Chronic Heart Failure Exhibit Hall 7:30 PM-9:00 PM Faculty and Fundraising Dinner Roman Ballroom Tuesday September 16 10:00 AM-2:00 PM Hands-on Workshop on Mitral Regurgitation 12:30 PM-1:15 PM Clinical Update 5:15 PM-6:00 PM Emergency Medicine Interest Group Closing the Gap on Thrombotic Events Exhibit Hall Wednesday September 17 8:15 AM-8:30 AM HFSA Business Meeting SE PT E MB ER 1 4- 17 L AS V E GAS , NE VA D A 2014 WELCOME 18th Annual Scientific Assembly $BFTBST1BMBDFt-BT7FHBT/7 4FQUFNCFSo SU N DAY, S E P T EM B E R 1 4 10:00 AM – 12:00 PM Milano I 10:00 AM – 12:00 PM Milano III Clinical Fundamentals I: Hemodynamics in Heart Failure: What You Need to Know (SCAI Joint Session) Contemporary Issues in Pulmonary Hypertension James C. Fang, Salt Lake City, UT Robb D. Kociol, Boston, MA Hemodynamic Domains: Pressure, Volume and Time John J. Ryan, Salt Lake City, UT Ioana Preston, Boston, MA Molecular Pathways In The Development of Pulmonary Hypertension Ioana Preston, Boston, MA Optimizing Hemodynamic Data Acquisition Genetic Determinants of Pulmonary Hypertension: When is Testing Appropriate? Mark H. Drazner, Dallas TX Evaluation and Treatment of Pulmonary Arterial Hypertension Teresa De Marco, San Diego, CA Physiologic and Pharmacologic Hemodynamic Assessments James C. Fang, Salt Lake City, UT Hemodynamics of Cardiogenic Shock Evaluation and Management of Pulmonary Hypertension in HFrEF Jonathan D. Rich, Chicago, IL Evaluating HFpEF in the Cath Lab Evaluation and Management of Pulmonary Hypertension in HFpEF Evaluating Pulmonary Hypertension Panel Discussion Assessing the Right Ventricle: Best Practices Gregory D. Lewis, Boston, MA OP E N IN G REC E PT I ON 6: 0 0 - 8: 00 P M E XHI BI T HAL L SU N DAY, S E P T EM B E R 1 4 10:00 AM – 12:00 PM Milano VII 3:00 PM – 5:30 PM Milano III Heart Failure Palliative Care: Critical Issues Can We Prevent Heart Failure? (AHA Joint Session) Erin K. Donaho, Houston, TX Managing the Patient through the HF Risk Assessment Beyond Comorbidities: Erin K. Donaho, Houston, TX The Role of Palliative Care in Heart Transplant and LVAD Evaluations Deborah Meyers, Houston, TX Palliative Care Pearls for the Heart Failure Team Ellin F. Gafford, Columbus, OH Prevention of Heart Failure: What’s New with Hypertension? Lifestyle Management to Reduce Heart Failure Risk: Is There a Role? Luc Djousse, Boston, MA Why Don't Patients Know They Have Heart Failure? The Role of Communication from Diagnosis to Death Beth Fahlberg, Madison, WI Management of Diabetes and Heart Failure Risk Biykem Bozkurt, Houston, TX Inotropes for Palliation of Advanced Heart Failure Symptoms Evaluation Before and Monitoring After Chemotherapy Where Are We with Operationalizing the Guidelines for End of Life Care? Sarah J. Goodlin, Portland, OR What Is the Role of Genetic Testing and Family Screening? Ray E. Hershberger, Columbus, OH Panel Discussion Faculty 12:00 PM – 2:30 PM Neopolitan I Hands-on Workshop on CRT: Indications, Optimization, Device Interrogation, Interpreting the Data, Troubleshooting (Limited enrollment, pre-registration required) Jagmeet Singh, Boston, MA Medtronic, and St. Jude Medical O PEN I N G R EC E PTI O N 6: 0 0 -8 : 00 P M E XHI BI T HAL L SU N DAY, S E P T EM B E R 1 4 3:00 PM – 5:30 PM Milano V 3:00 PM – 5:30 PM Milano VII Challenges in Caring for the Elderly Patient with a VAD (ICCAC-VAD Joint Session) Excellence in Basic Science: Translational Targets Move to the Clinic Tonya Elliott, Fairfax, VA Selection, Frailty and Outcomes: Destination Therapy in the Elderly When Are You Too Old for Heart Transplant and Just Right for LVAD Therapy? LVAD Evaluation of the Elderly Patient: Special Considerations Pamela S. Combs, Seton, TX Coordinating the Care of the Elderly Patient Following LVAD Implantation Tonya Elliott, Fairfax, VA Maria I. Kontaridis, Boston, MA Mark A. Sussman, San Diego, CA Tyrosine Kinase Inhibitors Exacerbate Post MI Remodeling GRK as a Novel Translational Target in Heart Failure Treatment Inhibition of G-protein Signaling in Treating Human Heart Failure Burns C. Blaxall, Cincinnati, OH MAPK Inhibitory Strategies in Treating Human Heart Disease Troponinl3kinase in the Heart... and Elsewhere Break Elders Caring for Elders: Supporting the Elder Caregiver Same, How It’s Different Justin Canada, Richmond, VA Bridge-to-Decision Patient Jeffrey J. Teuteberg, Pittsburgh, PA OP EN I N G RE C EP T I ON 6: 00 - 8: 00 P M E XHI BI T HA LL SU N DAY, S E P T EM B E R 1 4 3:00 PM – 5:30 PM Milano I 3:00 PM – 5:30 PM Neopolitan I Hemodynamic Impact of Drugs and Devices (SCAI Joint Session) Hands-on Workshop on CRT: Indications, Optimization, Device Interrogation, Interpreting the Data, Troubleshooting Richard Ha, Stanford, CA (Limited enrollment, pre-registration required) Hemodynamics of Continuous Flow LVADs Jagmeet Singh, Boston, MA Invasive Hemodynamics and LVAD Dysfunction Atman Shah, Chicago, IL Low Output Aortic Stenosis: What to Do in the TAVR Era Closing One Door Opens Another: Interventions for Functional MR Medtronic, and St. Jude Medical Complicated Hypotension 6:00 PM – 8:00 PM Exhibit Hall Hemodynamics of RV Failure Opening Reception and Poster Reception Presenters at posters: 6:30 -7:30 Temporary Mechanical Support in an Advanced Heart Failure Program Multi-vessel Revascularization in Advanced Heart Failure Frederick G. Welt, Salt Lake City, UT Panel Discussion Faculty 33 M O ND AY, S EP T E M BE R 1 5 6:30 AM – 7:30 AM Milano Foyer 7:00 AM – 8:00 AM Milano VII Light Breakfast Satellite Symposium: Imaging Sympathetic Innervation in Heart Failure: Window into Pathology and Outcome 7:00 AM – 8:00 AM Milano III Satellite Symposium: Hyponatremia In Heart Failure: Incorporating Practice Recommendations into Clinical Practice Barry H. Greenberg, San Diego, CA Welcome and Introduction Barry H. Greenberg, San Diego, CA A Primer on Imaging Innervation in Heart Failure Patients: How Is It Performed and Analyzed? Matthew J. Budoff, Los Angeles, CA Scope of the Problem Introduction of a Case The Role of MIBG Imaging in Heart Failure Risk Assessment Pathophysiology of Dilutional Hyponatremia, Including Symptoms of Mild to Moderate Hyponatremia Clinical Scenarios to Consider Imaging for Informing Challenging Decisions in the Clinic Barry H. Greenberg, San Diego Faculty Prognostic Implications of Hyponatremia, Potential Mechanisms of Causation Panel Discussion Faculty Putting Guidelines into Practice: Cases From the Real World Linda Ordway, Boston, MA Panel Discussion Faculty Pharmaceuticals, Inc. RE FRE SH M EN T BR E AK 10 : 00 AM E XHI B I T HA L L 34 M O ND AY, S EP T E M BE R 1 5 7:00 AM – 8:00 AM Milano V Satellite Symposium: Remote Monitoring of Patients with Heart Failure: New Developments 8:05 AM – 10:00 AM Augustus I Opening remarks Lifetime Achievement Award Welcome and Introduction Overview of Remote Monitoring of Heart Failure Patients Review of Clinical Trials of Implantable Hemodynamic Monitoring William T. Abraham, Columbus, OH Putting Implantable Hemodynamic Monitoring into Practice Panel Discussion Faculty Plenary Session: The Challenge of Care Disparities in Heart Failure Racial/Ethnic Disparities and Cross Cultural Care: The Role of Academic Centers Future Policy Strategies to Eliminate Disparities in Care Bruce Siegel, Washington, DC Bridging the Gap for Heart Health Disparities in Women Panel Discussion Faculty 10:00 AM – 4:00 PM Exhibit Hall Exhibit Hall Opens RE FRE SH M EN T BR E AK 10 : 00 AM E XHI B I T HA L L M O ND AY, S EP T E M BE R 1 5 10:30 AM – 12:00 PM Milano III 10:30 AM – 12:00 PM Augustus I Controversies and Challenges in Device Therapy (HRS Joint Session) Heart Failure Trials: The Year in Review William T. Abraham, Columbus, OH Eugene S. Chung, Cincinnati, OH Linda K. Ottoboni, Stanford, CA Jagmeet Singh, Boston, MA TOPCAT Bertram Pitt, Ann Arbor, MI Shrinking or Expanding? Leslie A. Saxon, Los Angeles, CA ROSE-AHF Enhancing Response in the CRT Non-Responder Kimberly A. Parks, Boston, MA CTSN – MR EXACT Device Therapy for Autonomic Modulation in the Heart Failure Patient: The Next Era for Devices? Panel Discussion Faculty Managing Pacing and Shocks to Improve LongTerm Outcomes in the Heart Failure Patient Ronald D. Berger, Baltimore, MD Panel Discussion Faculty Learning Objectie: gies. 36 M O ND AY, S EP T E M BE R 1 5 10:30 AM – 12:00 PM Milano VIII 10:30 AM – 12:00 PM Milano VII Predicition Is Hard, Especially About the Future: Dealing with Uncertainty in Risk Assessment Venous Congestion in Heart Failure: The Dark Side of the Moon Eldrin F. Lewis, Boston, MA Considering Risk for Outcomes other than Survival Kathleen Grady, Chicago, IL Quantifying Uncertainty in Risk Models Development of the Cardiorenal Syndrome in Heart Failure: Epidemiology and Outcomes The Role of Venous Congestion in the Pathophysiology of Acute Heart Failure Standardized Methods for Transmitting Uncertain Risk Estimates Shane J. LaRue, St. Louis, MO Abdominal Contributions to Renal Dysfunction in Heart Failure Grappling with Uncertainty in Discussions with Patients and Families Sara E. Wordingham, Scottsdale, AZ Hemodynamic Determinants of Dynamic Changes in Serum Creatinine in Acute Decompensated Heart Failure Case Discussion Eldrin F. Lewis, Boston, MA Hemoconcentration as a Treatment Goal in Acute Heart Failure Panel Discussion Faculty M O ND AY, S EP T E M BE R 1 5 10:30 AM - 1:00 PM Neopolitan I 12:15 PM -1:15 PM Milano V Hands-on Workshop: Acute Management of Cardiogenic Shock with Peripherally Implanted Devices How to Use Biomarkers in Clinical Practice (Limited enrollment, preregistration required) James L. Januzzi, Boston, MA Alan S. Maisel, San Diego, CA 12:15 PM – 1:15 PM Milano VIII How to Assess Frailty and Make Appropriate Activity Recommendations 12:00 PM – 1:30 PM Exhibit Hall See page 27 for a list of Clinical Updates, Hands-on Workshops, and other Exhibit Hall activities. 12:15 PM – 1:15 PM Milano VII How to Develop a Comprehensive Heart Failure Clinic in a Community Setting 12:15 PM – 1:15 PM Milano I How to Diagnose and Treat LVAD Complications Lee W. Jordan, Columbus, OH . Jonathan D. Rich, Chicago, IL M O ND AY, S EP T E M BE R 1 5 12:15 PM – 1:15 PM Milano III Rapid Fire Abstracts I New Therapies Mark H. Drazner, Dallas, TX LVAD and Transplant Comparison of Readmission Causes and Rates in Patients Supported with an Axial versus Centrifugal Flow LVAD Carolyn M. Rosner, Single Center Experience with Implantation of Permanent LVADs after VA ECMO Bridge in Patients with Acute Cardiogenic Shock Single Center Experience with Outpatient Continuous Infusion of Positive Inotropic Therapy . 1 Poloxamer 188 (MST-188) Elicits Prolonged Fraction and Suppresses Elevations of Plasma Troponin-I and nt-pro Brain Natriuretic Peptide in Dogs with Advanced Heart Failure 1 , Decreased Cardiac Allograft Survival in Patients Transplanted for Alcohol-Induced Cardiomyopathy: Data from the United Network for Organ Sharing (UNOS) Registry Sadeer Al-Kindi, Cardiac Arrhythmias in Patients with a Heart Ware Ventricular Assist Device 1 , 3 . Clinical Implications of The PR interval in Patients Hospitalized for Worsening Heart Analysis of The EVEREST Study Benjamin S. Wessler1, Haris Subacius Gheorghiade3 . 4 3 4 4 . 6 Oregon 3 4 6 Clinical and Pathologic Characteristics and Predictors of Myocarditis and Recovery in Patients Undergoing Endomyocardial Biopsy for Acute Onset Heart Failure Annual Screening with Select Coronary Angiography for Cardiac Allograft Vasculopthy (CAV) is Unnecessary in the Presence of a Normal Dobutamine Stress Echocardiography (DSE) Riociguat for HF with Pulmonary Hypertension (PH): Post-hoc Analysis of LEPHT by Baseline Pulmonary Vascular Resistance (PVR) and Pulmonary Vascular Gradient (PVG) Heart Transplantation: How “Late” Is It? 3 4 6 Francis Boateng Marc J. Semi M O ND AY, S EP T E M BE R 1 5 gran10. Malnutrition and Right Heart Failure: Chicken or Egg? 3 4 Frailty and Sacopenia in Older Patients with Advanced Heart Failure Miles D. Witham, Dundee, UK 6 SDF-1 Plasmid Attenuates Adverse Remodeling in Ischemic Heart Failure Patients in a Randomized Phase II Trial Eugene S. Chung1, Marc S. Penn 3 ations. 4 sohn Aras6 6 6 . 3 1:30 PM – 3:00 PM Milano VIII 4 6 Heart Failure in Adults with Congenital Heart Disease Luke J. Burchill, Portland, OR Karen K. Stout, Seattle, WA Types of Congenital Abnormalities and Surgical Interventions Leading to Heart Failure John Lynn Jefferies, Cincinnati, OH 1:30 PM – 3:00 PM Milano I Guideline Session: Defining Advanced Heart Failure to Anticipate Prognosis and Guide Therapy The Etiology and Prevalence of Heart Failure in Adults with Congenital Heart Disease Current Approach to Medical Therapy in the Congenital Heart Patient Karen K. Stout, Seattle, WA Surgical Support for Failing Congenital Heart Patients: Obstacles and Solutions to VADs Joshua L. Hermsen, Seattle, WA Guidelines Gregory A. Ewald, St. Louis, MO NYHA, WHO, INTERMACS, etc: Which Garrick C. Stewart, Boston, MA Transplant Outcomes in Patients with Congenital Disease: Who Does Well or Poorly, and Why? Luke J. Burchill, Portland, OR Panel Discussion Faculty Cardiorenal and Cardiohepatic Interactions Meredith A. Brisco, Charleston, SC Role of Percutaneous VADs in Clarifying the Destination RE FRE SH M EN T B RE AK 3 : 00 P M EXHI B I T HAL L M O ND AY, S EP T E M BE R 1 5 1:30 PM – 3:00 PM Milano V 1:30 PM – 3:00 PM Milano VII Heart Failure in Cancer Patients and Survivors: Prevention, Monitoring and Management Update on Stem Cell Clinical Trials Joshua M. Hare, Miami, FL Jean-Bernard Durand, Houston, TX Molecular Mechanisms of Cardiotoxicity Chemotherapy- Associated Heart Failure: How Often Does It Really Occur and Can It Be Prevented? Ronald M. Witteles, Stanford, CA Early Detection and Monitoring for the Development of Cardiomyopathy and Survivors Survivorship Programs Interdisciplinary Approach for the Management of Heart Failure in Cancer Patients Anecita P. Fadol, Houston, TX Dilated Cardiomyopathy? Joshua M. Hare, Miami, FL Update from Cardiovascular Cell Therapy Research Network (CCTRN) Do Endogenous Cardiac ckit Cells Really Make New Myocytes? Cardiac iPSCs: Clinical Trial in a Dish Next-generation Clinical Trials with Cardiosphere-derived Cells Eduardo Marban, Los Angeles, CA Translational Perspective from Animal Models with cKit Stem Cells Polina Goichberg, Boston, MA Panel Discussion Faculty strategies. RE FRE SH M EN T B RE AK 3 : 00 P M EXHI B I T HAL L M O ND AY, S EP T E M BE R 1 5 1:30 AM - 4:00 PM Neopolitan I 3:30 PM – 5:00 PM Augustus I Hands-on Workshop: Acute Management of Cardiogenic Shock with Peripherally Implanted Devices Late Breaking Clinical Trials (Limited enrollment, preregistration required) Prakash Deedwania, San Francisco, CA STEP-WISE: A Phase 2b Study Comparing Cross-linked Phyloelectrolyte (CLP) with Commentary - 3:30 PM – 5:00 PM Milano VIII Central Congestion in Obesity: Is the Heart an Innocent Bystander? Cardiovascular Effects of Adipokines Cardiopulmonary Effects of Obesity Hemodynamic Effects of Obesity Sarcopenic Obesity and Exercise Intolerance in Heart Failure Panel Discussion Faculty Autonomic Regulation Therapy to Enhance Myocardial Function in Heart Failure (ANTHEM-HF) Study Commentary Jagmeet Singh, Boston, MA Maintenance of Normokalemia with ZS-9 Once Daily in CHF Patients on RAAS Inhibitors Mohamed A. El-Shahawy, Los Angeles, CA Commentary Percutaneous Ventricular Restoration (PVR) Therapy Using the Parachute® Device in Patients with Ischemic Dilated Heart Failure: PARACHUTE III, European Post Market Trial--Primary Endpoint Results William T. Abraham, Columbus, OH ommentary James C. Fang, Salt Lake City, UT Serum Potassium Reduction and Prevention of Recurrent Hyperkalemia with Patiromer in Patients with Heart Failure and Chronic Kidney Disease on RAAS Inhibitors Bertram Pitt, Ann Arbor, MI Commentary Mark Drazner, Dallas, TX Prospective Comparison of ARNI with ACEI to Determione Impact on Global Mortality and orbidity in Heart Failure Trial (PARADIGM-HF) Milton Packer, Dallas, TX Commentary PO S TE R RE C EPT I ON 5 : 00 P M E XHI BI T HAL L M O ND AY, S EP T E M BE R 1 5 3:30 PM – 5:00 PM Milano V 3:30 PM – 5:00 PM Milano VII Trends and Treatment Options for LVAD Thrombosis Why the First Six Hours Are Not Like the Next 18 Hours (SAEM Joint Session) Stuart D. Russell, Baltimore, MD Incidence and Prevalence of Thrombosis in Continuous Flow LVADs The Importance of Early Management in the ED Deborah B. Diercks, Sacramento, CA Potential Factors Related to the Rise in Thrombosis Rates: What Happened? What Have We Learned from Recent Acute Heart Failure Trials? John R. Teerlink, San Francisco, CA Is There a Difference Between Continuous Flow LVADs? Jeffrey J. Teuteberg, Pittsburgh, PA Acute Management in the Observation Unit: The Ideal Patient and Ideal Location Peter S. Pang, Chicago, IL Diagnosis of LVAD Thrombosis: Is LDH the Best Biomarker? Gregory A. Ewald, St. Louis, MO AED Guidelines for Heart Failure: What Are They? Do They Need to Change? Gregg C. Fonarow, Los Angeles, CA Treatment Options for Pump Thrombosis: Anticoagulation, Exchange or Transplant Michael S. Kiernan, Boston, MA Not Your Typical Consent: Successful ED Clinical Trial Enrollment Gregory J. Fermann, Cincinnati, OH Panel Discussion Faculty Panel Discussion Faculty 5:00 PM – 6:30 PM Exhibit Hall Poster Reception 7:00 PM – 9:00 PM Roman Ballroom Faculty Reception and Dinner (All invited to attend. Tickets available at registration desk.) PO S TE R RE C EPT I ON 5 : 00 P M E XHI BI T HAL L 43 T U ESD AY, S EP T E M BE R 1 6 6:30 AM – 7:30 AM Milano Foyer 7:00 AM – 8:00 AM Milano V Light Breakfast Satellite Symposium: Heart Failure Patients with Mitral Regurgitation: New Guidelines, New Options 7:00 AM – 8:00 AM Milano III Satellite Symposium: Managing Hyperkalemia in Heart Failure: A Shifting Paradigm? JoAnn Lindenfeld, Aurora, CO Welcome and Introduction JoAnn Lindenfeld, Aurora, CO Welcome and Introduction Causes, Natural History Remodeling of the Mitral Valve Jonathan Beaudoin, Montreal, QC, Canada Risk of Hyperkalemia Domenic A. Sica, Richmond, VA Percutaneous Therapies for Mitral Regurgitation: Where We Are Now Michael Kim, Aurora, CO Insights into Novel Therapy for Hyperkalemia Gregg C. Fonarow, Los Angeles, CA Shifting the Paradigm of Hyperkalemia Man agement: Is It Necessary? Faculty Panel Discussion Panel Discussion Faculty RE FR ES H ME N T B R E A K 10 : 0 0 AM E XHIB I T HA L L 44 T U ESD AY, S EP T E M BE R 1 6 7:00 AM – 8:00 AM Milano I Clinical Fundamentals II: Beyond Peak Oxygen Consumption: New Insights into Cardiopulmonary Exercise Testing Marc J. Semigran, Boston, MA The Basics of CPET: Test Performance, Pitfalls and Interpretation Heart Failure and Lung Disease: Differentiating the Relative Roles of Cardiac and Pulmonary Reserve Bradley Maron, Boston, MA The Importance of VE/VCO2, Exercise Oscillatory Ventilation, and Oxygen Debt Recovery Gregory D. Lewis, Boston, MA CPET in Evaluating the HF Patient for Mechanical Support and Transplantation Stuart D. Russell, Baltimore, MD 8:10 AM – 10:00 AM Augustus I Clinical Excellence in Nursing Award Nursing Leadership Award Incoming President's Address JoAnn Lindenfeld, Aurora, CO Plenary Session: Comparative Effectiveness Research: The Time Has Come The Future of Comparative Effectiveness Research in the US Comparative Effectiveness Research in Heart Failure Can Comparative Effectiveness Research Be Accomplished with Observational Models? Panel Discussion Faculty 10:00 AM – 12:00 PM Neopolitan I 10:00 AM – 2:00 PM Exhibit Hall Exhibit Hall Opens Hands-on Workshop: Patient Selection, Management and Troubleshooting Durable Ventricular Assist Devices RE FR ES H ME N T B R E A K 10 : 0 0 AM E XHIB I T HA L L T U ESD AY, S EP T E M BE R 1 6 10:30 AM – 12:00 PM Milano I Case 4: Case Discussion Gina G. Mentzer, Columbus, OH Case 1: Case 5: Case 2: Case 6: Case 3: 46 T U ESD AY, S EP T E M BE R 1 6 10:30 AM – 12:00 PM Milano V 10:30 AM – 12:00 PM Milano VIII Heart Failure Clinical Trials: Future Challenges and Directions (Industry Session) JNC New Investigator Award: Basic Science Barry H. Greenberg, San Diego, CA Bertram Pitt, Ann Arbor, MI The Current State of Heart Failure Clinical Research in US Clinical Trial Participation: Future Challenges for Academic Medical Centers Mihai Gheorghiade, Chicago, IL Future Directions: The View from NHLBI Monica Shah, McLean, VA Douglas L. Mann, St. Louis, MO The Role of MLK3 in Inhibiting Cardiac Remodeling and Maintaining Left Ventricular Function After Pressure Overload Robert A. U. Baumgartner1, . The Matrix Metalloproteinase 13 - ProteaseActivated Receptor-1 Pathway Contributes to Doxorubicin-Induced Cardiotoxicity Future Directions: The Industry View Panel Discussion Faculty Delivery Method for Heart Failure Gene Therapy: Preliminary Study Featuring AAV9 Versus Standard Approaches Anthony S. Fargnoli1, . M-Atrial Natriuretic Peptide: A Novel Designer Natriuretic Peptide with Sustained Blood Pressure Lowering and Cyclic GMP Activating Actions in a Chronic Canine Model of Angiotensin II-Induced Hypertension 1 2 ,, T U ESD AY, S EP T E M BE R 1 6 10:30 AM – 12:00 PM Milano VII 6 JNC New Investigator Award: Clinical/ Integrative Pulmonary Vascular Response to Exercise in and Pulmonary Hypertension Frederik H. Verbrugge1, Low Pulsatility in the Early Post-Operative Setting Is Not Associated with Gastrointestinal Bleeding in Patients Supported with Left Ventricular Assist Devices Grieten . 3 3 Muscle Wasting in Patients with Heart Failure Impact on Muscle Strength and Functional Capacity during Exercise Tarek Bekfani1, 10:30 AM – 12:00 PM Milano III . Nursing Research Award Vascular Markers, Emerging Biomarkers in Muhammad Hammadah1, 3 . Kismet D. Rasmusson, Salt Lake City, UT 3 3 Linking Old and New Concepts: Iron and Bypass Graft Patients With or Without Pre-operative Heart Failure Ming Fen Tsai1, 3 . 3 Alok Sharma, Inorganic Nitrate Supplementation Improves Preserved EF - A Pilot Study Payman Zamani1, Cost Effectiveness of an Integrated Self Care Intervention for Persons with Heart Failure and Diabetes Carolyn M. Reilly1, 3 . 3 4 4 Can Medications Be Safely Withdrawn in Patients With Chemotherapy-induced Heart Failure With Recovered Heart Function? Anecita P. Fadol1, . 6 3 3 4 4 . T U ESD AY, S EP T E M BE R 1 6 3 4 Problem-Solving on Depressive Symptomatol ogy and Self-care Behaviors in Individuals with Heart Failure: A Structural Equation Modeling Study 1 , 12:15 PM – 1:15 PM Milano VIII How to Approach Difficult Conversations with Heart Failure Patients: Hoping for the Best, Planning for the Worst Ellin F. Gafford, Columbus, OH Ann S. Laramee, Burlington, VT . Palliative Care Services During Terminal Hospitalization: Stage D Heart Failure Patients Lisa A. Kitko, 12:15 PM – 1:15 PM Milano I-II How to Develop a Shared Care Program for LVAD Patients HF. Michael S. Kiernan, Boston, MA 12:00 PM – 1:30 PM Exhibit Hall 12:15 PM – 1:15 PM Milano V 12:15 PM – 1:15 PM Milano VII How to Run an Effective Clinical Research Program Eugene S. Chung, Cincinnati, OH Linda H. Martin, Cincinnati, OH How to Transition Patients into the Community Hilary Law, Seattle, WA Sheryl L. Chow, Los Angeles, CA T U ESD AY, S EP T E M BE R 1 6 12:15 PM – 1:15 PM Milano III Rapid Fire Abstracts II Diuretics/ Cardiorenal Robb D. Kociol, Boston, MA End of Life/ Shared Decision-Making Shared Decision-Making about End-of-Life Care for Heart Failure Patients with an Differential Cardiac versus Renal Response to Acute Volume Overload in Human Preclinical Systolic Dysfunction and Renal Dysfunction with the Combination of PDEV Inhibition and BNP Administration Isabel Torres Courchoud1, . Mayo National Cohort Study Debra Moser2. End of Life Resource Utilization in Heart Failure Patients with Preserved and Reduced A Stepwise Pharmacological Care Algorithm for Cardiorenal Syndrome for Acute Heart Failure: Insights from DOSE-AHF, CARRESS-HF, and ROSE-AHF 3 Shannon M. Dunlay, 4 6 6 W. H. Wilson Tang1. Patient-, Caregiver-, and Relationship-Level Care Maintenance Behaviors in PatientCaregiver Dyads Julie T. Bidwell1, 3 4 6 Mayo . 3 3 Preliminary Evaluation of the Heart Failure Screening Tool (Heart-FaST): Assessing for Patient Barriers to Engagement in Heart Failure Self-Care Jan Cameron, Reducing Heart Failure Admissions Through Heart Success Transitional Care Model Differential Hemodynamic Effects of Exercise and Acute Volume Expansion in HFpEF Mads J. Andersen1, . Transient and Persistent Worsening Renal Function during Acute Heart Failure Hospitalization: Insights from the ADHERE Registry Linked to Medicare Claims Arun Krishnamoorthy1,2, 3 3 Meghan E. Emig1. Learning from Heart Failure Patients to Improve Patient Centered Care Kismet Rasmusson, 4 . 3 4 T U ESD AY, S EP T E M BE R 1 6 Rapid Shallow Breathing Worsens Prior to Heart Failure Decompensation 3 4 4 4 John P. Boehmer . 5 1:20 PM – 3:00 PM Augustus I Announcement of Awards Jeffery Molkentin, Cincinnati, OH 3 4 Penn State Distal Tubular Compensation as an Important Mechanistic Site of Diuretic Resistance in Heart Failure Olga Laur1, . Hyde Park Session Late Breaking Clinical Trials: Results of the Multicenter Meaningful use and Underutilized Life Long Systems-improvements to Heart failure Intervention Study (MMM-BULLSHIS) Amrut V. Ambardekar, Aurora, CO Use Evidence-based Medicine: Stop Treating Acute Heart Failure! John R. Teerlink, San Francisco, CA How to Stop Poisoning and Love the (Redistribution) Syndrome New Study from New York Shows an Innovative Proprietary Intervention by the Gambino Family 12:30 PM – 2:30 PM Neopolitan I Hands-on Workshop: Patient Selection, Management and Troubleshooting Durable Ventricular Assist Devices Thoratec. Marriage and the LVAD: ‘Til Death Do Us Part? T U ESD AY, S EP T E M BE R 1 6 1:30 PM – 3:00 PM Milano III 1:30 PM – 3:00 PM Milano VII Challenges and Controversies in Heart Failure Pharmacology International Session Sheryl L. Chow, Los Angeles, CA The Anticoagulation Conundrum: Which Drug and When Chronic Heart Failure Analysis and Registry in the Tohoku District of Japan--The CHART Studies Management of Mineralocorticoids: Optimal Dosing and Avoidance of Complications Gregg C. Fonarow, Los Angeles, CA EchoCRT- Lessons Learned for Devices in Heart Failure Frank Ruschitzka, Zurich, Switzerland MRA in Patients with HFPEF: Mechanisms of Action and Implications for Future Therapy Bertram Pitt, Ann Arbor, MI LVAD Thrombosis--A Piece of the Puzzle JoAnn Lindenfeld, Aurora, CO Polypharmacy and Medication Complexity in Heart Failure Acute Heart Failure--Update 2014 Fibrotic Remodeling in the Ischemic Heart: Mechanisms to Address? RAAS Inhibition in Chronic Kidney Disease Panel Discussion Faculty Panel Discussion Faculty T U ESD AY, S EP T E M BE R 1 6 1:30 PM – 3:00 PM Milano VIII 3:30 PM – 5:00 PM Milano VIII Reverse Remodeling and Myocardial Recovery cGMP Activating Pathways in Heart Failure: Clinical and Basic Insights Douglas L. Mann, St. Louis, MO Robert Blanton, Boston, MA Marc J. Semigran, Boston, MA Basic Overview of Remodeling and Myocardial Recovery Basic Evidence for PDE5 Inhibition in Heart Failure Rakesh Kukreja, Richmond, VA Mechanisms of Reverse Remodeling Richard Ha, Stanford, CA Myocardial Natriuretic Peptide Signaling in Heart Failure: Basic Insights How to Diagnose and Predict Sustained Myocardial Recovery Scott D. Solomon, Boston, MA Nitric Oxide Donors in Heart Failure, Clinical Insights Mechanical Unloading of the Failing Human Heart: Atrophy or Recovery? Panel Discussion Faculty Abstracts/Posters of Interest: 3:00 PM – 5:00 PM Neopolitan I Hands-on Workshop: Patient Selection, Management and Troubleshooting Durable Ventricular Assist Devices Supported by educational grants from HeartWare and Thoratec. Clinical Evidence for PDE5 Inhibitors in Heart Failure Marc J. Semigran, Boston, MA Novel Natriuretic Peptides and Neprilysin Inhibitors in Heart Failure: Clinical Insights Downstream Targets of cGMP-dependent Protein Kinase I in Heart Failure Eiki Takimoto, Baltimore, MD T U ESD AY, S EP T E M BE R 1 6 3:30 PM – 5:00 PM Milano I Which Patients Do I Refer? Debates Regulatory and Legislative Update Linda Baas, Cincinnati, OH John R. Teerlink, San Francisco, CA James E. Udelson, Boston, MA Panel Discussion Faculty Pro: ICD Generators at ERI Should Be Replaced Even Though the LVEF Has Normalized Con: ICD Generators at ERI Should Be Replaced Even Though the LVEF Has Normalized Jagmeet Singh, Boston, MA Discussion Contraindication to Cardiac Transplantation Contraindication to Cardiac Transplantation Jon A. Kobashigawa, Los Angeles, CA Discussion 3:30 PM – 5:00 PM Milano V How to Select Patients for Advanced Therapies (ISHLT Joint Session) Are We There Yet? How to Determine When You Have Reached the Limits of Medical Therapy My Patient is on Inotropes But Has No JoAnn Lindenfeld, Aurora, CO Inotropes Aren't All Bad, Are They? 3:30 PM – 5:00 PM Milano VII Heart Failure and Cardiac Rehabilitation: What Clinicians Need to Know Ann S. Laramee, Burlington, VT What is the Evidence for Cardiac Rehabilitation in HFrEF and HFpEF? What Can Cardiac Rehab Do for My Patients with HF? LVAD vs. BiVAD vs. TAH: Who, What, When, Where and Why? Jeffrey J. Teuteberg, Pittsburgh, PA But She's a Healthy 70 Year Old! Panel Discussion Faculty W ED NE S D AY, S EP T E MB E R 1 7 7:00 AM – 8:15 AM Milano V 8:15 AM – 8:30 AM Neopolitan I Clinical Fundamentals III: The Basics of Mechanical Circulatory Support HFSA Business Meeting Axial and Centrifugal Continuous Flow LVADs: Differentiating Flow and Design Characteristics Francis D. Pagani, Ann Arbor, MI LVAD Implantation: Surgical Considerations Patient Selection: Assessment of End Organ Function and the Right Ventricle Short and Long-Term Complications of Continuous Flow LVADs Jennifer L. Peura, Charleston, SC BTT and DT Outcomes: Insights from INTERMACS Discharge Teaching and Outpatient Assessments Linda J. Ordway, Boston, MA 8:30 AM – 10:00 AM Milano VIII Emerging Roles for Advanced Imaging in Unexplained Cardiomyopathy for Idiopathic Dilated Cardiomyopathy The Role of EP Mapping to Guide Endomyocardial Biopsy in Unexplained Cardiomyopathy Newer MRI Techniques to Distinguish The Role of Positron Emission Tomography Imaging in Unexplained Cardiomyopathy Edward J. Miller, Boston, MA issues and care strategies. Panel Discussion Faculty RE FR ES H M EN T BREA K 1 0 : 00 AM M E E T I NG R OO MS FO YE R W ED NE S D AY, S EP T E MB E R 1 7 8:30 AM – 10:00 AM Milano V 8:30 AM – 10:00 AM Milano VII HFpEF: What We Do and Don't Know Improving Patient Satisfaction Scores: Strategies to Make Them Love You James C. Fang, Salt Lake City, UT Scott D. Solomon, Boston, MA J. Thomas Heywood, La Jolla, CA Introduction What Causes It? Quietness Campaigns How Do We Treat It? Bedside Rounds Panel Discussion Faculty The Compassionate Professional: The Heart of Patient Centered Care Joan Forte Scott, Stanford, CA What Success Looks Like Panel Discussion Faculty satisfaction scores. RE FR ES H M EN T BREA K 1 0 : 00 AM M E E T I NG R OO MS FO YE R W ED NE S D AY, S EP T E MB E R 1 7 8:30 AM – 10:00 AM Milano III 10:30 AM – 12:00 PM Milano III New Challenges in Cardiac Transplantation Not All Readmissions Should Be Avoided: When to Readmit Patients with Heart Failure Heart Allocation Policy in the US: Are There Opportunities for Improvement? Jon A. Kobashigawa, Los Angeles, CA Heart Transplantation in Amyloidosis: Update on Patient Selection and Outcomes Proliferation Signal Inhibitors: When and How Should We Be Initiating Therapy? New Strategies in Organ Preservation: An Update on PROCEED II Abbas Ardehali, Los Angeles, CA Panel Discussion Faculty Julie A. Shinn, Stanford, CA Perspectives from the Emergency Department Key Clinical Triggers for the Admission of Patients with “Worsening” Heart Failure Arrhythmic Indications for Heart Failure Admissions Linda K. Ottoboni, Stanford, CA The Patient on Mechanical Circulatory Support Linda J. Ordway, Boston, MA Case Studies Faculty RE FR ES H M EN T BREA K 1 0 : 00 AM M E E T I NG R OO MS FO YE R W ED NE S D AY, S EP T E MB E R 1 7 10:30 AM – 12:00 PM Milano V 10:30 AM – 12:00 PM Milano VII Right Ventricular Failure After LVAD Implantation 50 Shades of Technology in the Management of Heart Failure Keith D. Aaronson, Ann Arbor, MI Duc Thinh Pham, Boston, MA Current Epidemiology of Right Heart Failure After LVAD Implantation Robert Kormos, Pittsburgh, PA Medication Adherence: Emerging Use of Technology Prediction of Right Heart Failure: Clinical Models Can Heart Faillure Device Monitoring Be Done in the Home? Pathophysiology of RVF in LVAD Recipients Edwin C. McGee Jr., Chicago, IL I Can See You: The Use of TeleHealth Technology in HF Management Echocardiography as a Patient Selection Tool for LVAD: Where Do We Stand? Case Studies Keith D. Aaronson, Ann Arbor, MI Smartphones in Heart Failure Management S UND AY-M O ND AY, S EP T E M BE R 1 4 - 1 5 P O S TERS Cardiovascular Physiology ..................................................................................................................................... 040 Patients with Higher Fat Mass Have Longer Survival in Heart Failure 041 Abnormal Exercise Responses in Long-Term Survivors of Hodgkin Lymphoma Treated with Thoracic Irradiation: Evidence of Cardiac Autonomic Dysfunction and Impact on Outcomes 042 ROCK1 Plays an Essential Role in Doxorubicin-Induced Cardiotoxicity 043 Differences in Myocardial Sympathetic Innervation and Perfusion in Patients with Ischemic Versus Non-ischemic Heart Failure 3 4 . 3 4 044 - mental Model of Diabetic Cardio-Nephropathy 045 Congruity between Mental Stress-Induced and Adenosine-Induced Myocardial Ischemia Assessed Using SPECT in Heart Failure Patients . 046 Affected by Changes in Blood Volume During Hemodialysis Session 047 Cirrhotic Cardiomyopathy; Does It Really Exist? . 048 Volume Overload . S UND AY-M O ND AY, S EP T E M BE R 1 4 - 1 5 P O S TERS 049 Prognostic Value of Glomerular Filtration Estimates versus Natriuretic Response in Decompensated Heart Failure . 050 Role of Speckle Tracking Longitudinal Strain in Differentiating Stages of Diastolic Dysfunction 051 Relative Hypochromia is Associated with Disease Severity in Non-Anemic Patients with HF 3 3 . 3 Cardiovascular Structure ......................................................................................................................................... 052 Ventricular Fibrosis from Prolonged Bisphenol A Exposure 3 . 3 053 Relation of Epicardial Fat to Central Aortic Pressure and Left Ventricular Diastolic Function in Patients with Known or Suspected Coronary Artery Disease 054 The Role of Air Pollution upon Myocardial Remodeling Adriana M. O. Fonoff Pessoa . Neurohormones/Cytokines ..................................................................................................................................... 055 Neutrophil to Lymphocyte Ratio is Associated with Adverse Long Term Outcomes in Heart Failure Patients . 056 Patients with Heart Failure in the Beta-Blocker Era 057 Endothelin-1 Is Independently Associated with the Annual Risk of Heart Failure Hospitalization . S UND AY-M O ND AY, S EP T E M BE R 1 4 - 1 5 P O S TERS 058 Resistance and Type 2 Diabetes Mellitus . 059 Improving Anti-Oxidative Lactonase and Arylesterase Activities Predict Improved Long-Term Clinical Outcomes in Acute Decompensated Heart Failure 060 Stimulated B-Cell Products Induce Fibroblast Production of Promoters of Negative Remodeling- A Novel Concept of the Role of B-cells in Heart Failure Molecular Biology and Genetics ............................................................................................................................ 062 Dynamics in Circulating miRNAs Following Heart Transplantation and During Episodes of Cellular and Anti- 063 Endothelial Cells Have a Distinct Response to Continuous Flow Pump Support Compared to Pulsatile Flow Pump Support. A Gene Expression Analysis Study of Paired Myocardial Samples 064 Genetic Polymorphisms as Possible Factors Involved in the Onset of Anthracycline-Induced Cardiomyopathy 3 Rossi3 4 4 4 4 . 3 4 065 066 067 Fraction nus 3 . 3 4 4 4 S UND AY-M O ND AY, S EP T E M BE R 1 4 - 1 5 P O S TERS VADs/Transplant/Surgery .......................................................................................................................................... 068 3 4 6 Peura . 3 4 6 069 Impact of Hypertension on Continuous Flow-Left Ventricular Assist Device Outcomes 3 . 3 070 Cardiac cachexia as a predictor of length of stay in mechanical circulatory support . 071 Aortic Valve Replacement in Heart Failure Patients: Full Sternotomy or Minimally Invasive Access? . 072 Familial Cardiomyopathy is Associated with Better Cardiac Allograft Survival: Analysis from United Network for Organ Sharing (UNOS) 073 074 Outcomes of Heterotaxy Patients after Heart Transplantation with Complex Venous Reconstruction . 075 Increased Heart Rate Predicts Early Mortality in LVAD Patients 076 Predictors of Permanent Pacemaker Implant after Cardiac Transplantation: A Retrospective Analysis of a Contemporary Cohort S UND AY-M O ND AY, S EP T E M BE R 1 4 - 1 5 P O S TERS 077 Survival of Patients with a Left Ventricular Assist Device as a Bridge to Cardiac Transplantation is Independent of UNOS Listing Status 3 . 3 078 Determinants of Waiting List Time for Heart Transplantation: Is It All About Sensitization? 079 Mechanical Left Ventricular Support with the Impella 5.0: A Single Center Experience 080 Clinical Characteristics and Long Term Outcomes in Septuagenarians Undergoing Cardiac Transplantation 081 Does Etiology of Heart Failure Predict Orthostatic Hypotension in Patents with Left Ventricular Assist Device? 082 Left Ventricular Assist Devices and Changes in Leukocyte Count 3 4 4 . 4 3 4 083 Decreased Creatinine Production in Heart Failure Patients Undergoing LVAD Placement Leads to Overestimates of Renal Function Meredith A. Brisco . 084 Outpatient Management of Gastrointestinal Bleeding in Patients with Continuous-Flow Left Ventricular Assist Devices . 085 Smart Phone Enabled ECG Recording Can Scale for the U.S. Heart Failure Ambulatory Population . 63 S UND AY-M O ND AY, S EP T E M BE R 1 4 - 1 5 P O S TERS 086 Outcomes with Medical Management of Continuous Flow Left Ventricular Assist Device(CF-LVAD) Thrombosis . Electrophysiology and Rhythm Devices ........................................................................................................... 087 Right Ventricular Dysfunction - Predictor of Recurrence of Atrial Fibrillation after Pulmonary Vein Isolation 088 Change in QRS Duration Over Time Predicts Ventricular Tachycardia after Cardiac Resynchronization Therapy 089 - priate Shock after Generator Replacement 090 Ampere Hour (Ah) as a Predictor of CRT ICD Pulse Generator Battery Longevity. A Multi-Center Study 3 4 . 3 4 Clinical Trials ....................................................................................................................................................................... 091 SHIFT Trial 3 4 6 . 33 44 6 092 Cardiac Safety of the Sino Atrial Node f Channel Blocker Ivabradine in Chronic Heart Failure: An ECG-Holter Sub-study 64 S UND AY-M O ND AY, S EP T E M BE R 1 4 - 1 5 P O S TERS 093 Predictors of Anaemia-Development in Patients with Chronic Heart Failure: Results from the Studies Investigating Co-Morbidities Aggravating Heart Failure (SICA-HF) 094 Risk Factors of Anaemia-Development in Patients with Chronic Heart Failure: Results from the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF) 095 Design and Rationale of the Soluble Guanylate Cyclase Stimulator in Heart Failure Studies (SOCRATES) 3 Shah Roessig 4 6 . 3 4 6 Cardiovascular Pharmacology ............................................................................................................................... 096 097 - mization Strategies Evaluation in Acute Heart Failure (DOSE-AHF) Trial . 3 4 3 4 098 - comes in Acute Decompensated Heart Failure 3 . 4 4 4 3 4 099 Treating Rapid Atrial Fibrillation in Acute Decompensated Heart Failure: Metoprolol and Diltiazem are Equally Safe, yet Metoprolol Increases Conversion to Sinus Rhythm S UND AY-M O ND AY, S EP T E M BE R 1 4 - 1 5 P O S TERS 100 Hemodynamic Response to Continuous Outpatient Milrinone Infusion in Advanced Heart Failure Patients with Mixed Pulmonary Hypertension 3 er 3 . 3 101 Effect of Mineralocorticoid Receptor Antagonists on Cardiac Structure and Function in Patients with Diastolic Im3 4 . 3 4 Epidemiology, Prevention .......................................................................................................................................... 102 Serum Galectin-3 Is Elevated and Related to Cardiac Biomarkers in Types 2 Diabetes 103 A Single Center Experience in Racial Differences at the Time of Referral To Advanced Heart Failure Clinic 104 Substantial Proportion of Patients At Risk of Developing Heart Failure Have Elevated Natriuretic Peptide Levels: A Single-Center, Real-World Experience in a Preventive Cardiology Clinic 105 The Soluble Guanylate Cyclase Genetic Variant rs13139571 Is Associated with an “Unfavorable” Metabolic Phenotype in an US General Community 106 Hospital-Related Cardiac Morbidity among Survivors of Breast Cancer: Long-Term Risks and Predictors 3 4 Bride . 3 6 Brit 4 6 107 Recent Trends in Clinical Characteristics, Management and Prognosis of Patients with Dilated Cardiomyopathy in Japan -A Report from the CHART Studies. 66 S UND AY-M O ND AY, S EP T E M BE R 1 4 - 1 5 P O S TERS 108 Administrative Coding and Clinician Documentation of Mental Health Issues for Hospitalized Heart Failure Patients: Is There Agreement? 3 . 3 109 Filtration Rate: A Substudy of the HART Trial 110 Aldosterone: Marker and Predictor of Cardiorenal and Metabolic Disease in the General Community . 111 Rare in Singapore Outcomes .............................................................................................................................................................................. 112 Ischemic Cardiomyopathy Patients on Coumadin for Atrial Fibrillation Experience More Adverse Events with Clopidogrel or Percutaneous Coronary Intervention 113 To Improve Heart Failure (HF) Self-Management through Patients Group Clinic Appointments 114 Dipeptidyl Peptidase-4 Inhibitors Do Not Exacerbate Heart Failure . 115 Self-Reported Sleep Dysfunction is Associated with Worse Cardiac Event-Free Survival in Patients with Heart Failure 3 4 . 3 116 Digoxin Toxicity: Insights from 24,547 Cases 3 3 . 4 S UND AY-M O ND AY, S EP T E M BE R 1 4 - 1 5 P O S TERS 117 Contributors to Hospital Readmission Penalties 118 How Are Heart Failure Patients Engaging in Cognitive Activities? 3 . 4 3 4 119 Risk Assessment of Re-Hospitalizations for Heart Failure during 30 Days after Discharge for Acute Heart Failure 120 3 4 Murray 6 . 4 3 4 6 121 Clinical Characteristics and Outcomes of Patients with Discordant Findings at Right Heart Catheterization and Cardiopulmonary Exercise Testing . 122 Anemia Is Associated with Adverse Clinical Outcomes in Children Hospitalized with Acute Heart Failure . 123 an Ambulatory Heart Failure Clinic 124 Association of Worsening Renal Function with Length of Stay and Costs in Patients Hospitalized with Acute Heart Failure 3 . No 3 125 Teaching Hospitalists Might Provide Lessons on Optimizing Heart Failure Outcomes S UND AY-M O ND AY, S EP T E M BE R 1 4 - 1 5 P O S TERS 126 Characterization and Prediction of Adverse Events from Intensive Chronic Heart Failure Management with and without NT-proBNP Guidance: Results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study 3 . 3 127 Association between Depressive Symptoms and Emotional Well-Being Was Moderated by Gender, Not Caregiving Status, in Heart Failure Patient-Caregiver Dyads 128 The Feasibility of the Family Cognitive Educational Intervention to Improve Depressive symptoms and Quality of Life in Patients with Heart Failure and Their Family Caregivers 129 Computerized Auditory Cognitive Training Improved Cognition, Quality of Life, and Self-Care in Heart Failure: Report from a Pilot Study 130 Pre-Discharge BNP Predicts 30 and 60 Day Re-admissions in Patients with Decompensated Heart Failure 3 3 Sangita Sudharshan . 3 131 Relationship of Family Caregivers’ Perception of Patients’ Health Status and Time to Hospitalization for Decompensating Heart Failure 3 . 3 132 Severe Pre-Transplant Pulmonary Hypertension Is Not Associated with Detrimental Long-Term Survival after Heart Transplantation: Analyses from the UNOS Registry 133 Pulmonary Function Is Associated with Length of Stay and Survival in Patients Receiving Permanent Left Ventricular Assist Devices 134 Outcomes of CRT Stimulation at the Longest RV-LV Conduction Time . S UND AY-M O ND AY, S EP T E M BE R 1 4 - 1 5 P O S TERS 135 Regional Hospital Collaboration Is Associated with Reduced 30-Day Readmission in Medicare Heart Failure Patients 3 4 6 6 . St. 3 4 6 136 The Role of Nutritional Risk Index in Predicting Mortality in Advanced Heart Failure Patients 137 Clinical Variables Affecting Outcomes of Cardiac Resynchronization Therapy in Chronic Heart Failure 3 4 . 3 4 138 - nity Hospital Heart Failure Cohort 139 Chronic Kidney Disease and Higher Risk of 30-Day All-Cause Readmissions in Heart Failure: Findings from a Propensity-Matched Study 3 Prabhu 4 6 3 . 4 6 140 Renal Disease Undergoing Dialysis Clinical Care/Management Strategies ............................................................................................................... 141 Lack of Association Between Spironolactone Use and 30-Day All-Cause Readmission In Hospitalized Medicare Ben3 Prabhu 3 4 6 142 4 6 . S UND AY-M O ND AY, S EP T E M BE R 1 4 - 1 5 P O S TERS 143 Remote Monitoring of Physiologic Sensors in CRT-D Patients and Association to HF Hospitalizations and Survival . 144 The Clinical Nurse Leader: Establishing Relationships That Result in Decreased Heart Failure Readmissions 145 A Novel Palliative Care Program for Patients with Chronic Heart Failure That Decreased Readmission Rates 146 147 Prognostic Value of Body Fat Mass in Acutely Decompensated Heart Failure 150 Heart Failure and Palliative Care: Not Always a Good Fit . 151 The Development and Preliminary Implementation of a Protocol for the Outpatient Weaning of Milrinone 152 The Impact of Insomnia on Device Acceptance and Quality of Life in Cardiac Patients Living with an Implantable 3 4 3 4 . 153 Take-CHARGE: Heart Failure Discharge Electronic Form for Admission Characterization and Quality Improvement . 154 Peripherally Inserted Central Catheters Are Associated with Increased Risk of Adverse Events in Status 1B Patients Awaiting Transplantation on Continuous Intravenous Milrinone . 155 Evaluation of Tolvaptan Use in the Advanced Heart Failure Population S UND AY-M O ND AY, S EP T E M BE R 1 4 - 1 5 P O S TERS 156 Hospital Management of Hyponatremia in Patients with Heart Failure: Final Report from the HN Registry 157 Churg Strauss Syndrome with Hypersensitivity Myocarditis Progressing to Acute Necrotizing Eosinophilic Cardiomyopathy 158 Patients . PA 159 Revisiting Intravenous Inotropes: Are They as Bad as We Thought in Rematch . 160 Predictors of Development of Left Ventricular Thrombus After Acute Anterior Wall Myocardial Infarction 161 Discrete-Event Simulation (DES) to Evaluate and Improve the Performance of an Advanced Heart Failure/Transplant Clinic: A Real-Life Experience 162 Heart PACT: Patient Activation in High-Risk Patients with Heart Failure 163 Risk Factors for Readmission: A Community Hospital Experience 3 . 4 3 4 164 Low Literacy Self-Care Management Patient Education for a Multi-Lingual Heart Failure Population: Results of a Pilot Study 165 Disparity in Utilization of Hospice Services in a Heart Failure Program 3 . 4 3 4 S UND AY-M O ND AY, S EP T E M BE R 1 4 - 1 5 P O S TERS 166 Differences in Recovery of Functional Status Achieved by a Phase I Cardiac Rehabilitation Program in Patients with 167 A Resynchronization Optimization Clinic Improves Survival and Response of Heart Failure Patients Treated with Resynchronization Therapy 168 Fulminant Myocarditis . 3 3 169 A Survey of Knowledge and Perspectives of Ventricular Assist Device Therapy: Is Early Referral for Advanced Therapy Favorable among Cardiologists? 3 . 3 170 Prolonged Remote Monitoring Without In-Person Evaluation in Advanced Heart Failure Patients: Is There a Risk? . 171 The Amyloid Challenge: A Multidisciplinary Approach to Avoid Readmissions, Promote Self-Care, and Maintain Optimal Quality of Life 172 Inconsistency Between Different Measures of Sodium Intake in Patients with Heart Failure 173 Heart Failure Patients with More Anxiety Had More Total Energy, Protein, and Fat Dietary Intake 3 . 3 174 the COMPANION Study 3 4 6 3 4 6 175 Symptom Clusters and the Prediction of Hospitalization and Mortality in Patients with Heart Failure 3 4 . 3 4 S UND AY-M O ND AY, S EP T E M BE R 1 4 - 1 5 P O S TERS 176 Reduced Intrathoracic Impedance Correlates with Poor Renal Function in Heart Failure Patients 3 . 3 4 3 4 177 . 178 Two Heart Failure Admissions Within a Two Month Period MO N D AY-T U E SD AY, S E P T EM B E R 1 5 -1 6 P O S TERS Cardiovascular Physiology ................................................................................................................................... 180 Autonomic Regulation Therapy Titration Methodology Accelerates Adaptation to Low-Intensity Vagus Nerve Stimulation . 181 Pulmonary Arterial Capacitance and Pulmonary Vascular Resistance are Inversely Related and May Predict Mortality in Critically Ill Mechanically Ventilated Surgical Patients 182 Alterations in Left Atrial Structure, Phasic Function and Atrioventricular Coupling Impact Cardiac Performance in 183 - monary Vascular Reserve 184 Hemodynamic Basis for Exercise Intolerance in Right Heart Failure Due to Tricuspid Regurgitation 185 Graded Exercise Training to Assess Responsiveness in HFpEF Patients’ Peripheral EnDothelial Function Trial (GET RIPPED) Pilot Study . 186 An Evaluation of Right Ventricular Metabolism in Right Heart Failure Associated with Pulmonary Arterial Hypertension 187 The Novel Endothelin Receptor Antagonist, Macitentan, Improved Right Ventricular Function and Normalized Glucose Uptake in a Sugen5416/hypoxia Rat Model of Severe Pulmonary Artery Hypertension 188 The Reliability of 6-Minute Walk Test to Predict Peak Oxygen Uptake in Patients with Pulmonary Hypertension 3 3 . MO N D AY-T U E SD AY, S E P T EM B E R 1 5 -1 6 P O S TERS 189 Noninvasive Direct Lung Water Determination Using Novel Radiofrequency Technology 3 4 . 3 4 190 191 Right Ventricular Atrial Natriuretic Peptide Expression in End-Stage Human Heart Failure Cardiovascular Structure ..................................................................................................................................... 192 Right Ventricle Cytoskeletal and Contractile Protein Transcriptome in Human Heart Failure 193 3 4 4 4 6 4 4 . 6 3 3 4 6 194 Extracellular Volume Fraction and Noncontrast T1 Mapping Using 1.5-T Cardiac MRI in AL Cardiac Amyloidosis 195 Early Changes of Allograft Mass as Evidenced by Cardiac Magnetic Resonance (CMR) Imaging Technique in a Cohort of Post Heart Transplant Patients in the Current Era of Immunosuppression Neurohormones/Cytokines ..................................................................................................................................... 061 Diagnostic Performance of ST2 for Differentiating Cardiogenic versus Non-Cardiogenic Pulmonary Edema in Patients Presenting to the Intensive Care Unit with Hypoxic Respiratory Failure 3 . 3 4 6 196 Serum Leptin for Screening for Central Sleep Apnea in Heart Failure 4 6 MO N D AY-T U E SD AY, S E P T EM B E R 1 5 -1 6 P O S TERS 197 3 3 3 . 3 198 The Role of Soluble ST2 . 3 3 199 Aldosterone and Parathyroid Hormone in Heart Failure: Interaction and Prognosis Impact 200 - sated Heart Failure . 201 3 3 4 4 . 3 4 202 3 . 4 3 4 203 The Guanylyl Cyclase Receptor B and Cyclic GMP Activating Actions of a Unique Molecular Form of C-Type Natriuretic Peptide In Vitro and In Vivo MN Molecular Biology and Genetics .......................................................................................................................... 204 3 3 . 3 MO N D AY-T U E SD AY, S E P T EM B E R 1 5 -1 6 P O S TERS 205 PERSONALIZED MEDICINE: Prospective Patient Selection Utilizing an ADRB1 Genotype Assay in the GENETIC-AF Clinical Trial 206 3 . 3 207 Epigenetic Regulation of Gene Expression by Long Intergenic Non-Coding RNA Encoded by Cardiac Myosin Heavy Chain Genes 208 RNA Sequencing, Microarray Hybridization, and Quantitative PCR Produce Complementary, Concordant Results in Longitudinal Analysis of Myocardial Gene Expression in Dilated Cardiomyopathy Patients 3 4 . 3 4 VADs/Transplant/Surgery .......................................................................................................................................... 209 Acute Rehabilitation Is Effective in Patients with Left Ventricular Assist Device 3 4 . 3 4 210 Normalization of Left Ventricular Systolic Function After Cardiac Resynchronization Therapy (CRT) Minimizes ICD Therapy 3 4 4 6 . 3 4 211 Development and Use of a Human Induced Pluripotent Stem Cell Derived Cardiac Construct 212 Cost Comparison between Heart Transplantation and Left Ventricular Assist Device Implantation 6 MO N D AY-T U E SD AY, S E P T EM B E R 1 5 -1 6 P O S TERS 213 Plasma Neutrophil Gelatinase-Associated Lipocalin and Worsening Renal Function during Everolimus Therapy after Heart Transplantation 3 4 4 . 4 3 4 Graduate 214 YouTube as a Source of Information on Left Ventricular Assist Devices 3 . 3 215 Temporal Trends in the Incidence of Sudden and Non-Sudden Death after Heart Transplantation 216 Low Prevalence of Left Ventricular Thrombus in Patients Undergoing Ventricular Assist Device Evaluation . 3 3 217 Etiology and Timing of Readmissions After LVAD Implantation 218 Effects of Prolonged Postoperative Inotrope Administration after Left Ventricular Assist Device Implantation 3 4 . 3 4 219 220 Acquired and Hereditary Hypercoagulable States in Patients with Continuous Flow Left Ventricular Assist Devices: Prevalence and Thrombotic Complications . 221 Wearable Biometric Sensors and Cardiac Rhythm Management (CRM) Devices MO N D AY-T U E SD AY, S E P T EM B E R 1 5 -1 6 P O S TERS 222 Assist Device (CF-LVAD) Implant 223 - duced Cardiomyopathy 224 Change in Platelet Mitochondrial Membrane Potential 3 . 3 225 mTc Imaging Agent . 99 3 3 3 226 Preoperative Echocardiography Predicts Right Ventricular Failure After Implantation of Left Ventricular Assist Devices: Interim Results from a Prospective Cohort Study 227 Trends in Glomerular Filtration Rate (GFR) Following Implantation of Continuous Flow Left Ventricular Assist Devices (LVAD) . Electrophysiology and Rhythm Devices ......................................................................................................... 228 Role of Atrioventricular Junction Ablation in Patients with Atrial Fibrillation Undergoing Cardiac Resynchronization Therapy? - A Meta-Analysis 229 Noninvasive Lung Water Determination Using Novel Radiofrequency Technology: Clinical Validation 3 . 3 230 Catheter Ablation of Atrial Fibrillation Improves Left Ventricular Function in Patients with Left Ventricular Dysfunction . MO N D AY-T U E SD AY, S E P T EM B E R 1 5 -1 6 P O S TERS 231 Atrial Fibrillation Ablation in Patients with Severe Left Ventricular Dysfunction 232 Clinical Characteristics of Patients with Atrial Fibrillation on Long-term Ambulatory Monitoring Clinical Trials ..................................................................................................................................................................... 024 ZS-9 Once Daily Maintained Normokalemia in Patients with Hyperkalemia and Congestive Heart Failure 3 4 6 . Ac 3 4 6 233 - ney Disease: Results from the CHAMPION Trial 3 4 . 3 4 234 Lung Impedance-Guided Therapy of Patients with Chronic Heart Failure Improves Clinical Outcome 235 Considerable Regional Variation in AAV1 Neutralizing Antibodies and Its Consequences for a Multinational Clinical Trial of Gene Transfer for Advanced Heart Failure: The CUPID 2 Experience 3 4 Barry Greenberg 6 . 3 4 6 236 Differential Response to Low Dose Dopamine or Nesiritide in Patients with Acute Heart Failure and Renal Dysfunction in Accordance to LV EF: Sub-Group Analysis of the ROSE AHF Trial 3 A. Bart 6 3 4 3 4 6 3 . 6 MO N D AY-T U E SD AY, S E P T EM B E R 1 5 -1 6 P O S TERS Cardiovascular Pharmacology .............................................................................................................................. 237 Medications Have a Protective Role? 3 . 3 3 238 Torsemide vs. Furosemide in Heart Failure Patients: Insights from Duke University Hospital 239 - athy: A Look through Left-Ventricular Pressure-Volume Analyses 240 Vasomera™, a Novel VPAC2-Selective Vasoactive Intestinal Peptide Agonist, Improves Ventriculo-Arterial Coupling and Decreases Myocardial Demand in Sheep with Induced Ischemic Heart Failure 241 Low Dose Carperitide (alpha-hANP) Administration is Effective for Preventing Worsening Renal Function (WRF) and Long-term Renal Protection Epidemiology, Prevention .......................................................................................................................................... 242 Effects of Acute and Chronic Stress on Heart Failure Functional Status, Hospitalization and Mortality 3 . 4 3 4 243 Outpatient Intravenous Diuretic Therapy Avoids Emergency Department Visits and Hospital Admissions in a Northern Ontario Hospital 244 VA Cardio-Oncology Registry of Events in the Cardiovascular System (VA-CORE CV) Abbas Bitar . MO N D AY-T U E SD AY, S E P T EM B E R 1 5 -1 6 P O S TERS 245 Contemporary Secular Trends in the Nature of Heart Failure Admissions 246 Is Your Heart Ready for Another Holiday? . 247 248 Cardiotoxicity following Cancer Treatment: Linked Health Data Analysis 3 4 . 6 3 4 6 249 Getting the SCOOP - Survey of Cardiovascular Outcomes from Oncology Patients During Survivorship 3 . 3 250 Prognostic Impacts of Anemia in Patients with Chronic Heart Failure: An Interim Analysis of the CHART-2 Study 251 . 318 Heart Failure and Risk Factors: Examining the Effect of Ethnicity Variation and Age In California 3 4 . 3 4 Outcomes .............................................................................................................................................................................. 252 Patient Characteristics Associated with Serious Hyperkalemia in Veterans after Hospital Discharge with Heart Failure 3 . 3 253 Pulmonary Function Testing and Prognosis in Heart Failure Patients Listed for Heart Transplantation . MO N D AY-T U E SD AY, S E P T EM B E R 1 5 -1 6 P O S TERS 254 255 Triad of Health Status, Depression and Erectile Dysfunction in Heart Failure Patients: Is it Applicable to Hispanics? 256 Association of Therapeutic Effect on Functional and Physiological Markers and Change in Quality of Life in Patients 257 Elevated Left Ventricular End-Diastolic Pressure During Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction Patients Is a Predictor of Persistent Systolic Dysfunction . 258 Gender Differences in Risk of Neurologic Events during Support with Continuous Flow Left Ventricular Assist Device (LVAD) 259 Current Status of Adult Heart Transplant in Korea: Twenty-Year Experience 261 The RADIAL Score Predicts Primary Graft Failure and Total Mortality after Heart Transplantation 262 The Healthy Eating Index is Not a Predictor of Event-Free Survival in Patients with Heart Failure 263 The MAGGIC Heart Failure Risk Model Is Not an Effective Predictor of Outcomes in an Advanced Heart Failure Population 264 Electrolyte Depletion During Decongestive Treatment Adversely Impacts Outcomes of Acute Decompensated Heart Failure in a Contemporary Heart Failure Population . MO N D AY-T U E SD AY, S E P T EM B E R 1 5 -1 6 P O S TERS 265 Is There a “July Effect” in Heart Failure Readmissions? 266 Implantation . 3 3 267 Composite Risk Score Predicts Long-term Survival in Left Ventricular Assist Devices: A Move beyond INTERMACS . 268 Fraction: Results from the Korean Acute Heart Failure (KorAHF) Registry 269 Association with a Long Term Acute Care Hospital Improves Outcomes in High Risk Heart Failure Patients, a Single Center Experience 270 Post-Exercise Heart Rate Recovery Independently Predicts Clinical Outcome in Patients with Acute Decompensated Heart Failure 271 Left Ventricular Global Longitudinal Strain Predicts Mortality in African Americans with Heart Failure 272 PIIINP Predicts Mortality in African American Patients with Heart Failure 3 3 . 3 3 3 MO N D AY-T U E SD AY, S E P T EM B E R 1 5 -1 6 P O S TERS 273 Poor Right Ventricular Systolic Function (Lower TAPSE) and Higher Pulmonary Artery Systolic Pressure (PASP) Predicts Early Readmissions and All Cause Mortality in Elderly Patients with Heart Failure 274 The Role of Spironolactone in Real World Patients Hospitalized with Acute Decompensated Heart Failure . 3 3 275 Prognostic Value of Apolipoprotein A-II Levels in Patients with Heart Failure . 276 Reducing Heart Failure Readmissions: A Clinical Business Analytics Approach . Stan 277 Sustained Reduction in 30 Day All-Cause Heart Failure Readmission Rate for Consecutive Years in a Large Urban Hospital Utilizing a Multidisciplinary Team-Based Concurrent Risk Assessment and Mitigation Model 278 Culturally-Appropriate Education Can Improve Self-Care in Hispanic Patients with Heart Failure: A Pilot Study 3 . 3 279 280 High Sensitivity Troponin T (Hs-TnT) Predicts Outcomes in Patients Admitted with Acute Decompensated Heart . 3 3 Clinical Care/Management Strategies ............................................................................................................. 148 Utilizing Evidence-Based Methods to Exam Actual Salt Content in Diet with Heart Failure Patients 3 4 . 3 149 Symptom Burden in Patients Hospitalized for Decompensated Heart Failure 4 Na MO N D AY-T U E SD AY, S E P T EM B E R 1 5 -1 6 P O S TERS 281 First Look: The Stanford Integrated Psychosocial Assessment for Transplantation (SIPAT) and Association with Outcomes . Houston Methodist 282 - Louisville, KY . 283 Failure . 284 Functional Improvement Following Inpatient Rehabilitation in Patients with Left Ventricular Assist Devices 285 Impact of Multidisciplinary Personalized Disease Management Program on Readmission Rate after Discharge in Heart Failure Patients 286 Late Left Ventricular Systolic Function By Global Longitudinal Two-Dimensional Strain Imaging Among Survivors of Osteosarcoma Treated With Doxorubicin 287 Increased Resource Utilization in Left Ventricular Assist Device Patients with Gastrointestinal Bleeding Compared to Medical Controls 3 3 4 3 . 3 4 288 289 Association between Spirituality and Adherence to Multidisciplinary Management in Outpatients with Stable Heart Failure MO N D AY-T U E SD AY, S E P T EM B E R 1 5 -1 6 P O S TERS 290 Cardiac Magnetic Resonance- Guided Management Decreases Steroids Use in Patients with Recurrent Pericarditis . 291 Elevated PVR Is Associated with Improved 6-Month Survival in Patients on Continuous Milrinone Infusion as Destination Therapy 292 293 Addressing Health Literacy and Cultural Teaching Issues in Australian Indigenous and Non-indigenous Heart Failure Patients Using Avatars: Technology Development and Pilot Testing 3 4 6 . 3 4 6 294 A Simple Provider Education Tool Improves Heart Failure Knowledge and Discharge Process Measures . 295 A Structured, Electronic Medical Record Supported Post-Discharge Phone Call Reduces Heart Failure Readmissions Independent of Other Interventions 296 Feasibility and Acute Care Utilization Outcomes of a Post-Acute Transitional Telemonitoring Program for Underserved Heart Failure Patients 3 4 . 3 4 297 Characterization of the Clinical Spectrum in Patients Admitted for Acute Decompensated Heart Failure: Pilot Observations from a Single-Center Contemporary Real-World Experience 298 Heart Rate Control in Patients with Heart Failure and Left Ventricular Systolic Dysfunction, a Tertiary Center Experience . MO N D AY-T U E SD AY, S E P T EM B E R 1 5 -1 6 P O S TERS 299 with ST-Segment Elevation 300 Reducing All-Cause and Heart Failure Readmissions Using a Unique Collaborative Partnership of Hospital with Skilled Nursing Facilities and Home Care Agencies 3 . 3 301 Predicting Left Ventricular Recovery after VA ECMO Using Speckle Tracking 3 4 3 . 4 302 303 End of Life Perceptions of CHF Outpatients 304 Assessment of Timeliness of ICD/CRT Implant Using Automated EMR/Analytics . 305 An Integrated Self Care Education and Counseling Intervention for Persons with Heart Failure and Diabetes Improves Quality of Life and Physical Functioning 306 Dr. P. Phillips Hospital Outpatient Pharmacy Offers Heart Failure Pharmacy Bedside Consultation Services 307 Prognostic Impact of Preexisting Hypertension in Hospitalized Patient with Established Systolic Heart Failure MO N D AY-T U E SD AY, S E P T EM B E R 1 5 -1 6 P O S TERS 308 A Lack of Emphasis on EPHESUS: Describing Mineralocorticoid Usage in High Risk Myocardial Infarction 309 Assessment of Patient and Provider Perceptions Related to Heart Failure Readmissions 310 311 Giant Cell Myocarditis; Not Necessarily the Harbinger of Death 312 Predisposition to Thrombus Formation in Patients with Left Ventricular Assist Devices: The Minnesota Experience (Don’t Cha Know?) 313 Heart Failure Readmissions: How Low Can You Go? 314 Ambulatory Treatment of Heart Failure Decompensation by a Multidisciplinary Team Reduces Need for Hospital Admission 315 3 . 3 3 316 Specialized Exercise Prescription Program on Quality of Life and Functional Capacity with Heart Failure: Lessons Learned MO N D AY-T U E SD AY, S E P T EM B E R 1 5 -1 6 P O S TERS Late Breaking Clinical Trials ..................................................................................................................................... 319 Cost Effectiveness of Biventricular Pacing in Patients with Atrioventricular and Systolic Dysfunction: Analysis for the BLOCK-HF Clinical Trial 3 4 4 6 . 3 4 6 320 Myocardial Perfusion lmaging Sub-study of the C-Pulse System 321 C-Pulse System European Multicenter Study (OPTIONS-HF) 322 CHART-2 Study 323 Serelaxin in Acute Heart Failure: Sensitivity Analyses for the Primary Outcomes of the RELAX-AHF Trial 2014 EXHIBIT HALL 18th Annual Scientific Assembly $BFTBST1BMBDFt-BT7FHBT/7 4FQUFNCFSo E X HI B I T HAL L AC T I V I T I E S Clinical Updates Description: 2014 Clinical Updates Sunday, September 14, 6:30 PM – 7:15 PM decisions. Monday, September 15, 12:30 PM – 1:15 PM 3 Monday, September 15, 5:45 PM – 6:30 PM 3 Tuesday, September 16, 12:30 PM – 1:15 PM Sunday, September 14 6:30 PM – 7:15 PM Exhibit Hall 4 The Role of Neurohormonal Balance in Cardiac Remodeling and Progression of Heart Failure 4 4 Ernesto Schiffrin, MD, PhD, FRSC, FRCPC 6 Peter Liu, MD, FRCPC James Januzzi, Jr, MD References: Outline: ven E X HI B I T HAL L AC T I V I T I E S Clinical Updates Monday, September 15 Monday, September 15 12:30 PM – 1:15 PM Exhibit Hall 5:45 PM – 6:30 PM Exhibit Hall Considering Heart Rate in Cardiovascular Disease: A Focus on Heart Failure The Evidence Behind the Evidence: A Deeper Dive Into the Management of Chronic Heart Failure Speaker: Gregg C. Fonarow, MD, FACC, FAHA Speaker: Javed Butler, MD, MPH, FACC, FAHA Outline: Description: E X HI B I T HAL L AC T I V I T I E S Clinical Updates Hands-On Workshops Tuesday, September 16 12:30 PM – 1:15 PM Exhibit Hall Closing the Gap on Thrombotic Events Monday, September 15, 10:00 AM – 4:00 PM Description: Tuesday, September 16, 10:00 AM – 2:00 PM Monday, September 15 10:00 AM – 4:00 PM Exhibit Hall Sleep disordered breathing diagnosis and therapy hands-on workshop E X HI B I T HAL L AC T I V I T I E S Tuesday, September 16 10:00 AM – 2:00 PM Exhibit Hall Mitral Regurgitation from Diagnosis to Treatment: Patient Cases Instructors: Michele A. Hamilton, MD, and Asma Hussaini, PA-C, Cedars-Sinai, Los Angeles, CA This non-CME workshop is designed to provide information on mitral value disease and new treatment option. The discussion will address: education credits. E X HI B I T HAL L AC T I V I T I E S Clinical Trial Row Array BioPharma Inc CTR 5 ARRAY-797-251 ARRAY-797-231 Abbott Vascular CTR 1 COAPT study. BioControl Medical CTR 6 INOVATE-HF INOVATE-HF Alnylam Pharmaceuticals, Inc. CTR 2 DISCOVERY CTR 3 Amgen and Cytokinetics CTR 4 COSMIC-HF Cardiac Assist CTR 7 TRIS E X HI B I T HAL L AC T I V I T I E S Clinical Trial Row (continued) National Heart, Lung and Blood Institute – Heart Failure Network CTR 8 PAL-HF CTR 15 TACTICS (Investigator-initiated study with Duke Clinical Research Institute) CTR 9 FIGHT CTR 10 ATHENA-HF CTR 11 GUIDE-IT CTR 16 ATTR-ACT ResMed, Inc. CTR 17 CAT-HF CTR 12 IRON-OUT CTR 13 NEAT CAT-HF MV-ASV Otsuka America CTR 14 SECRET of CHF (Investigator-initiated study with Cardiovascular Clinical Studies Foundation) CTR 18 SERVE-HF E X HI B I T HAL L AC T I V I T I E S Clinical Trial Row (continued) SERVE-HF (MV-ASV) SynCardia Systems, Inc. CTR 20 SynCardia 50cc TAH-t Pediatric/Adult Study 50cc TAH-t Study Respicardia® Inc. CTR 19 SynCardia 70cc TAH-t Destination Therapy Study 70cc TAH-t DT Study E X HI B I T HAL L AC T I V I T I E S Exhibitor Listing with Booth Numbers ABC Trading Solutions Abiomed Alnylam Pharmaceuticals American Heart Association Amgen Amyloidosis Foundation Arbor Pharmaceuticals CardiacAssist, Inc. Cardiva Medical, Inc. CareDx, Inc. Coram CVS/Specialty Infusion Services Covis Pharmaceuticals Cytokinetics, Inc. DAXOR Corporation Elsevier Publishing Feel Good, Inc. Fresenius Medical Care GE Healthcare GLOBO-SA, Inc. Heart Failure Society of America HFSA E-mail Retrieval Stations Heart Genomics, LLC HeartWare, Inc. Hitachi Aloka Medical HRA Healthcare Research & Analytics Infinite Trading, Inc. Inrange Systems, Inc. LabCorp LUMEDX Medical Neurogenetics, LLC Medtronic, Inc. Millar, Inc. Miller Pharmacal Group, Inc. The Myocarditis Foundation NeuMeDx NI Medical Novartis Pharmaceuticals Corporation Novartis Pharmaceuticals Corporation On Track to Health Otsuka America Pharmaceuticals St. Jude Medical Sunshine Heart, Inc. SynCardia Systems, Inc. The Joint Commission The VAD Consulting Group Thoratec Corporation Walgreens Infusion Services Wolters Kluwer Health Zephyr-TEC Corporation ZOLL Booth #203 Booth #312 Booth #212 Booth #513 Booth #607 Booth #603 Booth #213 Booth #503 Booth #318 Booth #414 Booth #313 Booth #314 Booth #500 Booth #501 Booth #702 Booth #216 Booth #214 Booth #217 & 316 Booth #614 Promenade Hallway Exhibit Hall Booth #200 Booth #206 Booth #218 Booth #209 Booth #506 Booth #515 Booth #601 Booth #415 Booth #509 Booth #307 Booth #508 Booth #612 Booth #700 Booth #306 Booth #507 Booth #400 Booth #201 Booth #308 Booth #407 Booth #406 Booth #202 Booth #514 Booth #219 Booth #512 Booth #600 Booth #413 Booth #412 Booth #204 Booth #300 E X HI B I T HAL L AC T I V I T I E S Exhibitor Descriptions ABC Trading Solutions .................................................203 Amyloidosis Foundation……………………………603 Abiomed, Inc.…………………………………..……312 Arbor Pharmaceuticals…………...........……….....…213 Alnylam Pharmaceuticals……………….………….212 CardiacAssist, Inc…………………………………...503 American Heart Association……………....………...513 Cardiva Medical Inc………………………………...318 Amgen…………...................................……………….607 CareDx, Inc………………………………………….414 E X HI B I T HAL L AC T I V I T I E S Exhibitor Descriptions Feel Good, Inc. ..........................................……………216 Coram CVS/Specialty Infusion Services………..….313 Fresenius Medical Care- UF Complete…..…………214 Covis Pharmaceuticals, Inc…………………………314 GE Healthcare………..……….………………...217 & 316 Cytokinetics, Inc. …………………………………...500 GLOBO-SA, Inc.………..……….……………………...614 DAXOR Corporation…………………...…………..501 Heart Genomics, LLC………………………………200 Elsevier Publishing …………………………….....…702 E X HI B I T HAL L AC T I V I T I E S Exhibitor Descriptions (located in the Promenade Hallway) The Joint Commission………………………………219 HFSA E-mail Retrieval Stations……..……Exhibit Hall HeartWare, Inc…………………………..………….206 LabCorp………………………………….........…….601 Hitachi Aloka Medical……………………………....218 LUMEDX………………………………….......…….415 HRA Healthcare Research & Analytics………………..…209 Medical Neurogentics, LLC…………....…………....509 Inrange Systems, Inc…………..………...…………..515 E X HI B I T HAL L AC T I V I T I E S Exhibitor Descriptions Medtronic, Inc…………………………....….………307 NI Medical……………………………….………….507 Millar, Inc………………………..…………………..508 Medical Novartis Pharmaceuticals Corporation……….....…400 Miller Pharmacal Group, Inc………………………612 Novartis Pharmaceuticals Corporation……………201 OnTrack to Health…………………………………..308 The Myocarditis Foundation……………………….700 Otsuka America Pharmaceutical, Inc. ………...…...407 NeuMeDx……………………………................……..306 E X HI B I T HAL L AC T I V I T I E S Exhibitor Descriptions St. Jude Medical……………………………………..406 Walgreens Infusion Services…………………...……413 Sunshine Heart……………………….……………..202 Wolters Kluwer Health………………………..…….412 SynCardia Systems, Inc……………………………..514 Zephyr-TEC Corporation………………….……….204 The VAD Consulting Group………………..……….512 "Harness ZOLL……………………..…………………...…….300 Thoratec Corporation.............………………………600 2014 THANK YOU 18th Annual Scientific Assembly $BFTBST1BMBDFt-BT7FHBT/7 4FQUFNCFSo 20 14 H FS A AN NU AL SCI ENT I FI C M E ET I NG Faculty/Author Index SE PT E MB ER 1 4- 17 L AS V E GAS , NE VA D A 20 14 H FS A AN NU AL SCI ENT I FI C M E ET I NG Faculty/Author Index SE PT E MB ER 1 4- 17 L AS V E GAS , NE VA D A 20 14 H FS A AN NU AL SCI ENT I FI C M E ET I NG Faculty/Author Index SE PT E MB ER 1 4- 17 L AS V E GAS , NE VA D A 20 14 H FS A AN NU AL SCI ENT I FI C M E ET I NG Faculty/Author Index SE PT E MB ER 1 4- 17 L AS V E GAS , NE VA D A 20 14 H FS A AN NU AL SCI ENT I FI C M E ET I NG Faculty/Author Index SE PT E MB ER 1 4- 17 L AS V E GAS , NE VA D A 20 14 H FS A AN NU AL SCI ENT I FI C M E ET I NG Faculty/Author Index SE PT E MB ER 1 4- 17 L AS V E GAS , NE VA D A 20 14 H FS A AN NU AL SCI ENT I FI C M E ET I NG Faculty/Author Index SE PT E MB ER 1 4- 17 L AS V E GAS , NE VA D A 20 14 H FS A AN NU AL SCI ENT I FI C M E ET I NG Faculty/Author Index SE PT E MB ER 1 4- 17 L AS V E GAS , NE VA D A 20 14 H FS A AN NU AL SCI ENT I FI C M E ET I NG Faculty/Author Index SE PT E MB ER 1 4- 17 L AS V E GAS , NE VA D A 20 14 H FS A AN NU AL SCI ENT I FI C M E ET I NG Faculty/Author Index SE PT E MB ER 1 4- 17 L AS V E GAS , NE VA D A 20 14 H FS A AN NU AL SCI ENT I FI C M E ET I NG Faculty/Author Index SE PT E MB ER 1 4- 17 L AS V E GAS , NE VA D A 20 14 H FS A AN NU AL SCI ENT I FI C M E ET I NG Faculty/Author Index SE PT E MB ER 1 4- 17 L AS V E GAS , NE VA D A 20 14 H FS A AN NU AL SCI ENT I FI C M E ET I NG Faculty/Author Index SE PT E MB ER 1 4- 17 L AS V E GAS , NE VA D A 20 14 H FS A AN NU AL SCI ENT I FI C M E ET I NG Faculty/Author Index SE PT E MB ER 1 4- 17 L AS V E GAS , NE VA D A 20 14 H FS A AN NU AL SCI ENT I FI C M E ET I NG Faculty/Author Index SE PT E MB ER 1 4- 17 L AS V E GAS , NE VA D A 20 14 H FS A AN NU AL SCI ENT I FI C M E ET I NG Faculty/Author Index SE PT E MB ER 1 4- 17 L AS V E GAS , NE VA D A 20 14 H FS A AN NU AL SCI ENT I FI C M E ET I NG SE PT E MB ER 1 4- 17 L AS V E GAS , NE VA D A 20 14 H FS A AN NU AL SCI ENT I FI C M E ET I NG Exhibit Hall Floor Plan HEART FAILURE SOCIETY OF AMERICA SEPTEMBER 14 - 16, 2014 CAESARS PALACE - OCTAVIUS BALLROOM LAS VEGAS, NV ENTRANCE 200 Heart Genomics, LLC 201 Novartis Pharmaceuticals Corporation 400 300 ZOLL 202 Novartis Pharmaceuticals Corporation 500 Cytokinetics, Inc. 501 600 Thoratec DAXOR Corporation Corporation 601 LabCorp 503 603 CardiacAssist, Inc Amyloidosis Foundation 506 507 NI Medical 607 508 509 Sunshine Heart, Inc. 700 The Myocarditis Foundation 702 Elsevier, Inc 204 Zephyr-TEC Corporation 206 HeartWare, Inc. 203 209 HRA Research & Analytics 212 Alnylam Pharmaceuticals 214 Fresenius Medical Care 216 306 ABC Trading NeuMeDx Solutions 213 Arbor Pharmaceuticals, LLC 307 406 Medtronic, St. Jude Inc. Medical 407 Otsuka America Pharmaceuticals 308 Millar, Inc. On Tack to Health 312 Abiomed, Inc. Covis Pharmaceuticals 314 Infinite Trading, Inc. 313 Coram CVS/ Specialty Infusion Services 412 Wolters Kluwer Health CareDx, Inc. 414 413 512 Walgreens The VAD Infusion Consulting Group Services 415 514 SynCardia LUMEDX Systems, Inc. Amgen Medical Neurogenetics, LLC 513 612 Miller American Heart Pharmacal Association Group 515 Inrange Systems, Inc. 614 GLOBOSA, Inc. EMAIL STATION 20' x 30' Feel Good, Inc. 218 Hitachi Aloka Medical 217 CLINICAL TRIAL ROW 219 316 318 Cardiva Medical, Inc. HANDS ON WORKSHOP 12 POSTER BOARDS CLINICAL UPDATES 14 SE PT E MB ER 1 4- 17 L AS V E GAS , NE VA D A 20 14 H FS A AN NU AL SCI ENT I FI C M E ET I NG Caesars Floor Plan PROMENADE LEVEL I To Exhibit Hall & Augustus EMPERORS LEVEL NEOPOLITAN BALLROOM II V III IV VII VIII MILANO BALLROOM I SPEAKER READY ROOM VERONA Office 6 II EMPERORS BALLROOM PRESS ROOM TREVI VENICE Freight Elevators Registration Desk SPEED MENTORING FLORENTINE BALLROOM Business Kiosks Banquet Kitchen Freight Elevators I Elevators Phones Elevators GENOA Meeting Services Office 2 Promenade FACULTY DINNER & FUNDRAISING EVENT ROMAN BALLROOM Business Kiosks REGISTRATION Escalators MESSINA CAPRI Office 5 Office 3 LIVORNO EDITORIAL BOARD MEETING TARRANTO Escalators COUNCIL/COMMITTEE MEETING ROOM CONSUL SENATE BOARDROOM BOARDROOM Office 1 PRE FUNCTION 1 MODENA SIENA SICILY I PALERMO Elevators PRE FUNCTION 2 COUNCIL/COMMITTEE MEETING ROOM PISA AUGUSTUS BALLROOM I IMPERIAL SALERNOSORRENTO BOARDROOM Registration Desk Office 4 HFSA INFO BOOTH III A II PALACE BALLROOM B III ANZIO SE PT E MB ER 1 4- 17 L AS V E GAS , NE VA D A 20 14 H FS A AN NU AL SCI ENT I FI C M E ET I NG Notes SE PT E MB ER 1 4- 17 L AS V E GAS , NE VA D A 20 14 H FS A AN NU AL SCI ENT I FI C M E ET I NG Notes SE PT E MB ER 1 4- 17 L AS V E GAS , NE VA D A 20 14 H FS A AN NU AL SCI ENT I FI C M E ET I NG Notes SE PT E MB ER 1 4- 17 L AS V E GAS , NE VA D A 20 14 H FS A AN NU AL SCI ENT I FI C M E ET I NG 2014-2015 Calendar ........................................................................................................................................................ HFSA Dates to Remember April 2015 October 2014 S M T W 1 8 15 22 29 5 12 19 26 6 13 20 27 7 14 21 28 S M T W 2 9 16 23 30 3 10 17 24 4 11 18 25 5 12 19 26 S 7 14 21 28 M 1 8 15 22 29 S M T W 4 11 18 25 5 12 19 26 6 13 20 27 7 14 21 28 S 1 8 15 22 M 2 9 16 23 T 3 10 17 24 S 1 8 15 22 29 M 2 9 16 23 30 T 3 10 17 24 31 T 2 9 16 23 30 F 3 10 17 24 31 S 4 11 18 25 T F 6 13 20 27 7 14 21 28 S 1 8 15 22 29 F 5 12 19 26 S 6 13 20 27 F 2 9 16 23 30 S 3 10 17 24 31 F 6 13 20 27 S 7 14 21 28 F 6 13 20 27 S 7 14 21 28 S M T 5 12 19 26 6 13 20 27 7 14 21 28 S M T W T 3 10 17 24 31 4 11 18 25 5 12 19 26 6 13 20 27 7 14 21 28 S 7 14 21 28 M 1 8 15 22 29 T 2 9 16 23 30 W 3 10 17 24 31 T 4 11 18 25 S M T 5 12 19 26 6 13 20 27 7 14 21 28 S M T 5 12 19 26 March 2015 W 4 11 18 25 T 5 12 19 26 F 1 8 15 22 29 S 2 9 16 23 30 T W 2 9 16 23 30 3 10 17 24 31 4 11 18 25 5 12 19 26 W 3 10 17 24 F 5 12 19 26 S 6 13 20 27 F 3 10 17 24 31 S 4 11 18 25 T F 6 13 20 27 7 14 21 28 S 1 8 15 22 29 T 4 11 18 25 W 1 8 15 22 29 T 2 9 16 23 30 August 2015 February 2015 W 4 11 18 25 S 4 11 18 25 July 2015 January 2015 T 1 8 15 22 29 F 3 10 17 24 June 2015 December 2014 T 2 9 16 23 30 T 2 9 16 23 30 May 2015 November 2014 February 8-14, 2015 W 1 8 15 22 29 Note: meeting starts on Saturday September 2015 S M 6 13 20 27 7 14 21 28 T 1 8 15 22 29 W 2 9 16 23 30 SE PT E MB ER 1 4- 17 L AS V E GAS , NE VA D A T 3 10 17 24 F 4 11 18 25 HFS A Mark ’15 Cale Your ndar S 5 12 19 26 HEART FAILURE SHATTERS MILLIONS OF LIVES Chronic heart failure is a growing crisis—with little improvement in hospitalization rates or mortality outcomes over the last 10 years.1,2 VISIT BOOTH 201 TO LEARN MORE References: 1. Heidenreich PA, Albert NM, Allen LA, et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail. 2013;6(3):606-619. 2. Go AS, Mozaffarian D, Roger VR, et al. Heart disease and stroke statistics—2014 update: a report from the American Heart Association. Circulation. 2014;129(3):e28-e292. Novartis Pharmaceuticals Corporation East Hanover, New Jersey 07936-1080 © 2014 Novartis Printed in USA 8/14 LZ6-1306945
